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ABSTRACT 
 
 Background: In 1990, the National Institutes of Health released the first published 
guidelines for the treatment of rectal cancer, which recommended chemo-radiation 
therapy in the postoperative setting for patients with stage II and III of the disease. Since 
then, numerous studies have suggested the superiority of neoadjuvant chemo-radiation 
therapy in terms of local control, acute and long-term toxic effects, patient compliance, 
and sphincter preservation. As a result, the current standard of care for patients with stage 
II and III rectal cancer has become neoadjuvant chemo-radiation therapy followed by 
surgery with curative intent. The objective of this research is to evaluate the changes 
made to the clinical practice of rectal cancer over time by comparing the effects of 
neoadjuvant chemo-radiation therapy to standard therapy on patient survival and disease 
recurrence.  
 
Methods: We examined the clinicopathological data for a sample of 757 confirmed 
cases of rectal adenocarcinoma collected from 1 of 3 cohorts: the Newfoundland 
Colorectal Cancer Registry from 1997 to 2003, the Ontario Familial Colorectal Cancer 
Registry from 1997 to 2000, and the single practice of a general surgeon working in 
Newfoundland and Labrador from 1993 – 2014. The primary outcome of our study was 
overall survival in patients with stage II and III of the disease, which was measured from 
the date of diagnosis to the date of death. We investigated the effect of neoadjuvant 
chemo-radiation therapy on overall survival for these patients.  
  
 iii 
   
 Results: For patients with stage I-IV rectal cancer, age, anterior resection surgery, 
complete excision, grade, vascular and perineural invasion, and stage were independent 
predictors of overall survival (p < 0.05). For patients with stage II and III of the disease, 
age, anterior resection surgery, complete excision, grade, stage, and the presence of 
perineural invasion were independently associated with overall survival (p < 0.05). Again, 
no significant association between neoadjuvant therapy and patient survival was observed 
independent of these variables. The rate of neoadjuvant chemo-radiation therapy was 
significantly higher for stage II and III patients diagnosed after December 2003 (5% vs. 
41%, p < 0.001). For this cohort, age, sex, stage, and vascular invasion were independent 
significant predictors of overall survival (p < 0.05). Again, neoadjuvant chemo-radiation 
therapy had no significant effect on survival. However, the relative risk for neoadjuvant 
chemo-radiation therapy was 0.428 (p= 0.107).  
 
 Conclusions: In the cohort with stage II and III rectal cancer diagnosed after 2003, 
the magnitude of the relative risk for neoadjuvant chemo-radiation suggested benefit, but 
it did not achieve statistical significance because of the inadequate power caused by the 













   
Acknowledgements 
Firstly, I would like to thank my research supervisor, Dr. Patrick Parfrey, an 
individual whom I admire both personally and professionally. Thank you for your 
guidance throughout each stage of my project and for providing me with an education that 
was unparalleled. Thank you for helping me to further my own knowledge of research 
methodology and interpretation using your expertise. Lastly, thank you for your 
unwavering patience and positive influence as one of my role models. 
To Dr. Elizabeth Dicks, my co-supervisor: You were my first mentor in the 
Clinical Epidemiology program, where you helped me achieve my academic goals time 
and time again. Thank you for always being available to discuss my project, for giving 
me numerous opportunities to grow as an individual, and for wanting the best for me. 
You gave me a job at a research study, encouraged me to pursue higher education, and 
taught me a lot about life in general by being both a co-supervisor and a friend.  
To Dr. William Pollett, my co-supervisor: Thank you for sharing your expertise in 
colorectal surgery with our group and for helping me translate this knowledge to my 
thesis. Thanks for taking a substantial amount of time to help me improve the quality of 
my dataset and for always providing me with encouragement throughout my studies.  
To Mrs. Andrea Kavanagh and Mrs. Susan Ryan, thank you for your help with 
data linkages and for your advice related to the management and organization of my 
dataset. To my family and friends, thank you for pushing me to finish my thesis and for 
your unconditional support of all of my endeavors. Thank you to my parents for instilling 
the value of education in me from an early age. To the patients enrolled in this research 
project, thank you for your selfless contribution, necessary to make this research possible.  
 
Table of Contents 
ABSTRACT ....................................................................................................................... ii 
Acknowledgements ........................................................................................................... iv 
List of Tables ...................................................................................................................... v 
List of Figures ................................................................................................................. viii 
List of Abbreviations & Symbols ...................................................................................... x 
Chapter 1: INTRODUCTION .......................................................................................... 1 
1.1 Aim of the study ....................................................................................................... 3 
Chapter 2: LITERATURE REVIEW .............................................................................. 4 
2.1 Background information ......................................................................................... 5 
2.2 Definition, diagnosis, & staging of rectal Cancer .................................................. 6 
Tumor .......................................................................................................................... 9 
2.3 Patient Candidacy for treatment .......................................................................... 10 
2.4 Historical Advances in Rectal Surgery ................................................................ 11 
2.5 Adjuvant therapy ................................................................................................... 14 
2.51 Radiation therapy ............................................................................................... 14 
2.52 Concurrent chemotherapy .................................................................................. 15 
2.6 Recurrent disease ................................................................................................... 17 
2.7 Prognostic factors ................................................................................................... 20 
2.71 Surgical margins ................................................................................................ 20 
2.72 Presence of lymphovascular and perineural invasion ........................................ 21 
2.73 Histological grade of tumor ............................................................................... 23 
2.8 Mortality ................................................................................................................. 24 
Summary of Literature Review ...................................................................................... 26 
Chapter 2: METHOD ...................................................................................................... 27 
3.1 Study Approval ...................................................................................................... 27 
3.2 Ascertainment ........................................................................................................ 27 
3.3 Data Collection ....................................................................................................... 29 
3.4 Statistical Analysis ................................................................................................. 30 
Chapter 4: RESULTS ...................................................................................................... 32 
4.1 Description of study sample .................................................................................. 32 
4.2 Outcome measurements by patient cohort .......................................................... 35 
4.3 Univariate predictors of survival and of recurrence .......................................... 41 
4.4 Multivariate models of survival and disease recurrence .................................... 45 
4.4.3 Multivariate model of disease recurrence-free time to event ............................ 47 
4.5 Analysis by stage of disease ................................................................................... 48 
4.5.2 Analysis of outcomes for stage IV patients ...................................................... 56 
4.6 Analysis of patients with stage II and III rectal cancer ...................................... 60 
  
  
   
4.6.1 Baseline demographics by patient cohort ......................................................... 60 
4.6.2 Outcome measurement by patient cohort ......................................................... 63 
4.7 Analysis of stage II and III patients by neoadjuvant therapy ........................... 69 
4.7.1 Overall survival and recurrence outcomes ........................................................ 69 
4.7.2 Univariate predictors of outcome .......................................................................... 75 
4.7.3 Multivariate models of outcomes .......................................................................... 80 
4.8 Analysis of patients with stage II and III disease following December 2003 .... 84 
4.8.1 Baseline demographics ..................................................................................... 84 
4.8.2 Overall survival and recurrence outcomes ........................................................ 85 
4.8.4 Univariate predictors of outcome ...................................................................... 91 
4.8.4 Multivariate predictors of outcome ................................................................... 95 
Chapter 5: DISCUSSION ................................................................................................ 98 
5.1 Predictors of survival and recurrence by patient cohort ................................... 98 
5.2 Predictors of survival and recurrence by stage of disease ............................... 103 
5.3 Predictors of survival and recurrence of patients with stage II & III rectal 
cancer by cohort ......................................................................................................... 105 
5.4 Predictors of survival and recurrence of patients with stage II and III rectal 
cancer by neoadjuvant therapy ................................................................................ 108 
5.5 Conclusions of study and future directions ....................................................... 115 
References ....................................................................................................................... 119 
Appendinces .................................................................................................................... 133 
    Appendix A: Health research ethics authority approval……………...………….133 



















List of Tables 
 
Table 1: Baseline Clinical & Pathological Characteristics of cohorts…………...…..34 
 
Table 2: Overall Survival at Follow-up by Patient Cohort………………………......35 
 
Table 3: Time to local recurrence by cohort for patients of all stages…………........37 
 
Table 4: Disease-free time to event by cohort for patients of all stages……...……...39 
 
Table 5: Results for univariate analysis of overall survival for patients of all 
stages………………………………………………………………………….......……..42 
 
Table 6: Results for univariate analysis of local recurrence-free time to event for 
patients of all stages…………………………………………………………………….43 
 
Table 7: Results for univariate analysis of disease-free time to event for patients of 
all stages……………………………………………………………………………........45 
 
Table 8: Results of multivariate analysis of overall survival for patients with rectal 
cancer of all stages……………………………………………………………………....46 
 
Table 9: Results of multivariate analysis of local recurrence-free time to event for 
patients with rectal cancer of all stages………………………………………………..47 
 
Table 10: Results of multivariate analysis of disease-free time to event for patients 
with rectal cancer of all stages…………………………………………………………48 
 
Table 11: Overall survival by cohort and stage……………………………………....49 
 
Table 12: Local-recurrence-free time to event by cohort and stage…………............50 
 
Table 13: Disease-free time to event by cohort and stage………………………........50 
 
Table 14: Overall survival by cohort for patients with stage I rectal cancer….........51 
 
Table 15: Time to local recurrence-free time to event by cohort for patients with 
stage I rectal cancer………………………………………………………………..........53 
 
Table 16: Disease-free time to event by cohort for patients with stage I rectal 
cancer……………………………………………………………………………….........55 








Table 17: Overall survival by cohort for patients with stage IV rectal 
cancer…………………………………………………………………………………….57 
 
Table 18: Disease-free time to event by cohort for patients with stage IV rectal  
Cancer……………………………………………………………………………………59 
 
Table 19: Baseline clinical & pathological characteristics by cohort for stage II and 
III patients……………………………………………………………………………….63 
 
Table 20: Overall survival by cohort for patients with stage II & III rectal 
cancer…………………………………………………………………………………….64 
 
Table 21: Local recurrence-free time to event by cohort for patients with stage II & 
III rectal………………………………………………………………………………….66 
 
Table 22: Disease-free time to event by cohort for patients with stage II & III rectal 
cancer…………………………………………………………………………………….68 
 
Table 23: Overall survival by neoadjuvant therapy status for patients with stage II 
& III rectal cancer………………………………………………………………………70 
 
Table 24: Local recurrence-free time to event by neoadjuvant therapy status for 
patients with stage II & III rectal cancer……………………………………………...72 
 
Table 25: Disease-free time to event by neoadjuvant therapy status for patients with 
stage II & III rectal cancer…………………………………………………………......74 
 
Table 26: Results of univariate analysis of overall survival for patients with stage II 
& III rectal cancer………………………………………………………………………77 
 
Table 27: Results of univariate analysis of local recurrence-free time to event for 
patients with stage II & III rectal cancer……………………………………………...78 
 
Table 28: Results of univariate analysis of disease-free time to event for patients 
with stage II & III rectal cancer …………………………………………………….....80 
 
Table 29: Results of multivariate analysis of overall survival for patients with stage 
II & III rectal cancer………………………………………………………………..…..81 
 
Table 30: Results of multivariate analysis of local recurrence-free time to event for 
patients with stage II & III rectal cancer………………………………………….......82 
 








Table 31: Results of multivariate analysis of disease-free time to event for patients 
with stage II & III rectal cancer………………………………………………………..83 
 
Table 32: Predictors of neoadjuvant chemo-radiation therapy for patients with stage 
II & III rectal cancer post December 2003……………………………………………85 
 
Table 33: Overall survival for patients with stage II & III rectal cancer diagnosed 
post-December 2003………………………………………………………………….....86 
 
Table 34: Local recurrence-free time to event for patients with stage II and III rectal 
cancer diagnosed post-December 2003…………………………………………….…..88 
 
Table 35: Time to disease-free time to event for patients with stage II and III rectal 
cancer diagnosed post-December 2003………………………………………………...90 
 
Table 36: Results of univariate analysis of overall survival for patients with stage II 
& III rectal cancer diagnosed post-December 2003…………………………………..92 
 
Table 37: Results of univariate analysis of local recurrence-free time to event for 
patients with stage II & III rectal cancer diagnosed post-December 2003……….....93 
 
Table 38: Results of univariate analysis of disease-free time to event for patients 
with stage II & III rectal cancer diagnosed post-December 2003………………........94 
 
Table 39: Preliminary results of multivariate analysis of overall survival for patients 
with stage II & III rectal cancer diagnosed post-December 2003………………........95 
 
Table 40: Final model of multivariate analysis of overall survival for patients with 
stage II & III rectal cancer diagnosed post-December 2003…………………………96 
 
Table 41: Results of multivariate analysis of disease-free time to event for patients 















List of Figures 
 
Figure 1: Tumor node metastasis standardized staging system (TNM) classification 
of colorectal cancer………………………..…………………………….…………..........9 
 
Figure 2: Kaplan-Meier curves of overall survival by patient cohort for patients of 
all stages……………………………………………………………………………….....36 
 
Figure 3: Kaplan-Meier curves of local recurrence-free time to event by patient 
cohort for patients of all stages……….……………………………………………......38 
 
Figure 4: Kaplan-Meier curves of disease-free time to event by patient cohort for 
patients of all stages…………………………………………………………………......40 
 
Figure 5: Kaplan-Meier curves of overall survival by cohort for patients with stage I 
rectal cancer………………………………………………………………………..........52 
 
Figure 6: Kaplan-Meier curves of local recurrence-free time to event by cohort for 
patients with stage I rectal cancer …………………………………………………......54 
 
Figure 7: Kaplan-Meier curves of disease-free time to event by cohort for patients 
with stage I rectal cancer……………………………………………………………….56 
 
Figure 8: Kaplan-Meier curves of overall survival by cohort for patients with stage 
IV rectal cancer…………………………………………………………………………58 
 
Figure 9: Kaplan-Meier curves of disease-free time to event by cohort for patients 
with stage IV rectal cancer…………………………………………………………......60 
 
Figure 10: Kaplan-Meier curves of overall survival by cohort for patients with stage 
II & III rectal cancer……………………………………………………………….…...65 
 
Figure 11: Kaplan-Meier curves of local recurrence-free time to event by cohort for 
patients with stage II & III rectal cancer………………………………………….......67 
 
Figure 12: Kaplan-Meier curves of disease-free time to event by cohort for patients 
with stage II & III rectal cancer………………………………………………….…….69 
 
Figure 13: Kaplan-Meier curves of overall survival by neoadjuvant therapy status 
for patients with stage II & III rectal cancer………………………………………….71 
 








Figure 14: Kaplan-Meier curves of local recurrence-free time to event by 
neoadjuvant therapy status for patients with stage II & III rectal cancer………….73 
 
Figure 15: Kaplan-Meier curves of disease-free time to event by neoadjuvant 
therapy status for patients with stage II & III rectal cancer.………………………...75 
 
Figure 16: Kaplan-Meier curves of overall survival for patients with stage II & III 
rectal cancer diagnosed post-December 2003…………………………………………87 
 
Figure 17: Kaplan-Meier curves of local recurrence-free time to event for patients 
with stage II and III rectal cancer post-December 2003……………………………...89 
 
Figure 18: Kaplan-Meier curves of disease-free time to event for patients with stage 




























                                       








          List of Abbreviations  
 
 
AJCC American Joint Committee for Cancer  
 
APR Abdominal Perenial Resection 
 
AR   Anterior Resection 
 
CINAHL Cumulative Index of Nursing and Allied Health     
      Literature  
 
CRC Colorectal Cancer 
 
CRM Circumferential Resection Margin 
 
CRT  Chemoradiation Therapy  
 
CT Computed Tomography 
 
ERUS Endorectal Ultrasound 
 
IUCC International Union for Cancer Control 
 
MeSH Medical Subject Heading 
 
MRI Magnetic Resonance Imaging  
 
NFCCR Newfoundland & Labrador Colorectal Cancer Registry 
 
OFCCR Ontario Familial Colorectal Cancer Registry 
 
TME  Total Mesorectal Excision 
 
TNM Tumor Node Metastasis Standardized Staging System
 
   
1 
Chapter 1: INTRODUCTION 
 
 Colorectal Cancer (CRC) is one of the most prominent and deadly diseases in the 
western world today (Madlensky, 2004). During 2019, it was estimated that 26, 300 
Canadians were diagnosed with CRC and that 9, 500 Canadians died from the disease  
(Canadian Cancer Society, 2020). Approximately 30% of all CRC cases can be attributed 
to patients with rectal cancer, who have been historically susceptible to developing 
locally recurrent disease following surgical intervention (Ucar, 2013; Kapiteijn, 2001; 
Van den broek, 2013). To account for this high rate of local recurrence, William Heald 
developed the principles of Total Mesorectal Excision (TME), which were subsequently 
incorporated into the standard surgical care for patients with locally advanced rectal 
cancer, stages II (T3-4, N0, M0) and III (any T, N1-2, M0). These principles, which 
involve a complete resection of the mesorectum and surrounding lymph nodes, have been 
shown to improve both local control and patient survival (Rodríguez-Luna, 2015).  
Prior to the 1980s, surgery was often the sole treatment for stage II and III rectal 
cancer, which resulted in a 5-year patient survival rate of just 50% (Yorio, 2012; Fisher 
1988). Since then, management has evolved to incorporate a multidisciplinary régime, 
which includes chemotherapy, radiation therapy, and definitive surgery (Krook, 1991). 
The efficacy of postoperative chemoradiation therapy (CRT) was first established from 
the results of three prospective randomized controlled trials, which were conducted by the 
Gastrointestinal Tumor Study Group, the Mayo/North Central Cancer Treatment group, 
and the National Surgical Adjuvant Breast and Bowel Project. These studies showed that 
patients, who were treated with postoperative CRT, benefited from improvements in 
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disease-free and overall survival in comparison to individuals treated with surgery alone. 
As a result, the 1990 U.S. National Institute of Health consensus conference on the 
treatment of CRC recommended post-operative CRT for the treatment of stage II and III 
rectal cancer (NIH consensus conference, 1990).  
During the 1990s, studies demonstrated the superiority of preoperative, or 
“neoadjuvant”, radiation therapy for patients with locally advanced rectal cancer in 
regards to local control (Frykholm, 1993; Swedish Rectal Cancer Trial, 1997). However, 
these trials began before the standardization of TME and therefore, the results may have 
been due to changes in surgical technique itself. In 2001, the Dutch Colorectal Cancer 
Group designed a prospective randomized trial with standardized surgical procedure to 
deal with this issue. Although their results showed that neoadjuvant radiotherapy 
significantly reduced the rates of local recurrence among patients, no improvement in 
patient survival was observed (Kapiteijn, 2001). In 2004, the German Rectal Cancer 
Study group published the results of their seminal paper that compared neoadjuvant and 
postoperative CRT. The results of the 5-year follow up favored neoadjuvant CRT in terms 
of local control, acute and long-term toxic effects, patient compliance, and sphincter 
preservation (Sauer, 2004). As a result, clinical practice began to favor a recommendation 
of neoadjuvant CRT followed by radical surgery for patients with stage II and III rectal 
cancer (de Campos-Lobato, 2011; Lim, 2008; Pahlman, 2009).  
There is a need for ongoing research to examine the change in clinical practice 
following the recommendation of neoadjuvant CRT. Further studies that compare patient 
survival before and after this change in practice will benefit the prognosis and future 
management of patients with locally advanced rectal cancer. 
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1.1 Aim of the study 
The objective of this study is to examine overall survival for patients, with stage II 
& III rectal cancer, inhabiting Newfoundland & Labrador and Ontario during the 
period of 1993 – 2014. The study will compare overall survival before and after the 
changes in clinical practice from postoperative to neoadjuvant CRT. 
 
Specifically, the main objectives are: 
1. To examine the rate of overall survival in stage II and III rectal cancer patients 
following the change in clinical practice from postoperative to neoadjuvant CRT; 
 
2. To examine the rate of disease-free time to event in stage II and III rectal cancer 
patients following the change in clinical practice from postoperative to neoadjuvant 
CRT; 
 
3. To examine the rate of local recurrence-free time to event in stage II and III rectal 
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Chapter 2: LITERATURE REVIEW 
 
This literature review summarizes the published research findings that have 
impacted the management of patients with stage II and III rectal cancer. A computerized 
literature search was conducted using The Cochrane Library, PubMed, and Cumulative 
Index of Nursing and Allied Health Literature (CINAHL) databases. The Cochrane 
Library was used to search for relevant meta-analysis and systematic reviews, finding 
several papers that provided an overview of the key findings pertinent to the research 
question.  Next, PubMed and CINAHL were consulted for meta-analysis and reviews by 
specifying the publication type, and then for original research articles. Search strategies 
included key words “rectal cancer”, “colorectal cancer”, “rectal carcinoma”, “TNM 
staging”, “pathologic”, “preoperative”, “postoperative”, “abdominoperineal resection”, 
“anterior resection”, “total mesorectal excision”, “rectal cancer surgery”, “sphincter-
saving surgery”, “stoma”, “multimodality therapy”, “recurrent”, “local recurrence”, 
“margin”, “spread”, “treatment”. Medical Subject Heading (MeSH) terms included 
“rectal neoplasms”, “chemoradiotherapy”, “radiotherapy”, “neoadjuvant therapy”, 
“recurrence”, and “mortality”, “survival”, “history”. The focus of this review was to 
familiarize the investigator with information pertaining to the management of rectal 
cancer. An expert in the field of colorectal surgery was consulted to attain knowledge of 
the therapies that are currently available to patients with locally advanced stages of the 
disease. This information was also used to ensure the selection of appropriate papers. This 
literature review is limited to only those articles published in English as of March 2020. 
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2.1 Background information 
Rectal cancer, which accounts for approximately 30% of colorectal cancer (CRC) 
cases, is a leading cause of cancer mortality in the western world. Most individuals that 
are diagnosed with rectal cancer present with locally advanced disease, which are stages 
II and III. As a result, these patients are at an increased risk of local recurrence following 
surgery (Agarwal, 2013; Gunderson, 2010). Unfortunately, locally recurrent disease is 
frequently inoperable and patients who relapse often suffer a painful death (Nagtegaal, 
2002). Consequently, a primary goal for rectal cancer treatment has become optimizing 
local control (Lin, 2013). In an attempt to improve local control and survival among 
patients with stage II and III rectal cancer, treatment has evolved to incorporate a multi-
modal regime that includes chemotherapy, radiotherapy, and radical surgery.  
In 1990, the U.S. National Institutes of Health released the first evidence-based 
guidelines for the treatment of patients with CRC. Based on the results of three 
randomized controlled trials, the standard care for patients with locally advanced disease 
became rectal surgery followed by postoperative CRT. However, this recommendation 
was premature and highly criticized (Pasetto, 2004). In 2004, Sauer et al. published one of 
the most influential articles to the field of rectal cancer treatment, suggesting neoadjuvant 
CRT to be more beneficial in terms of local control, acute and long-term toxic effects, 
patient compliance, and sphincter preservation. As a result, patients with stage II and III 
rectal cancer now undergo neoadjuvant CRT followed by radical surgery that 
incorporates the principles of TME. Although neoadjuvant CRT has improved the rates of 
local control in patients with locally advanced stages of the disease, it remains unclear 
whether an association exists between neoadjuvant therapy and improved patient survival. 
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2.2 Definition, diagnosis, & staging of rectal Cancer 
Previous studies have reported differences in the treatment of CRC due to 
surgeon-specific variables (McMullen, 2005; Hool, 1998; Hyman, 2007). For example, 
there has been considerable debate between surgeons regarding the definition of the 
rectum, its length, and the site of transition from rectum to sigmoid colon (Kenig, 2013). 
A study by McMullen et al. reported disagreement between surgeons who were asked to 
define the proximal and distal boundaries of the rectum. While 30% of respondents 
defined the upper boundary of the rectum in terms of distance from the anal verge, 66% 
used some other anatomic landmark to define this boundary. Similarly, 76% of 
respondents defined the distal boundary in terms of an anatomic landmark and another 
23% described the distal boundary as anything below their definition of the upper 
boundary (McMullen et al, 2005). In 2010, Chuah et al. surveyed all general surgeons in 
Atlantic Canada to determine their preferences for screening and neoadjuvant assessment 
of rectal cancer. Their results also showed variability in the surgeon’s definition of the 
rectum. Out of 82 respondents, 31% defined the rectum as at or below the peritoneal 
reflection, while another 27% defined it in terms of the coalescence of the tenia. 
Interestingly, 26% considered the rectum to be 15 cm within the anal verge and another 
16% described it as the region below the sacral promontory. Furthermore, some 
respondents chose multiple answers to define the rectum (Chuah, 2010). The definition of 
the rectum is important for differentiating rectal cancers from cancers of the sigmoid 
colon. At present, many authors agree that rectal cancer can be defined as a tumor with its 
lower edge within 15cm of the anal verge (Ucar, 2013; Glimelius, 2013).  
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Most diagnoses of rectal cancer are made during colonoscopy after the patient 
presents to clinic with anemia, change in bowel habit, or blood in the stool. In addition, 
the cancer must be confirmed pathologically, as strictures and inflammatory diseases are 
benign conditions that may present similarly (Trakarnsanga, 2012). Following 
pathological diagnosis, the most common tests ordered are Computed Tomography (CT) 
scans of the chest, abdomen, and pelvis. CT imaging is useful for determining metastatic 
spread of the disease to lung, liver, pelvic, and periaortic lymph nodes, though it cannot 
accurately assess tumor penetration or nodal involvement (Trakarnsanga, 2012). The 
staging of rectal cancer is clinically important for deciding whether multi-modal therapy 
is necessary (Schrag, 2013). Staging refers to the size and extent of the primary tumor (T 
stage), the nodal involvement (N stage), and the spread of the disease (M stage). In an 
effort to organize patients into prognostic groups, the Tumor Node Metastasis 
standardized staging system (TNM) was collaboratively developed by the International 
Union for Cancer Control (IUCC) and the American Joint Committee for Cancer (AJCC). 
At present, the TNM is the most used staging system globally (Obrocea, 2011). Table 1 
describes the TNM of CRC.  
Adequate clinical staging begins with a digital rectal exam in order to determine 
the location and mobility of the lesion, the latter relating to the tumors penetration of the 
rectal wall. Most often, rigid sigmoidoscopy is used to better determine the distance of the 
primary tumor, which is measured from the anal verge (Trakarnsanga, 2012). For 
determining T and N staging, endorectal ultrasound (ERUS) and pelvic magnetic 
resonance imaging (MRI) represent the gold standard of care. MRI can be used to 
describe in detail the level, localization, shape, and extramural growth of bulky rectal 
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tumors, whereas ERUS is used to describe small, superficial tumors (Trakarnsanga, 
2012). Once the tumor is surgically excised, it is sent to a lab for more accurate, 
pathological staging. In addition, lymphadenectomy is performed during surgery and the 
removed lymph nodes are used to determine the level of nodal involvement (Sauer, 2004; 
Kapiteijn, 2001; Roh, 2009). The IUCC and the AJCC have recommended the 
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Tumor 
• T1: Submucosa 
• T2: Muscularis propria 
• T3: Subserosa, perirectal tissues 
• T4a: Visceral peritoneum 
• T4b: Other organs or structures 
Lymph Node 
• N1a: One regional lymph node involved 
• N1b: Two to three regional lymph nodes involved 
• N1c: Satellites without regional lymph nodes 
• N2a: Four to six regional lymph nodes involved 
• N2b: Seven or more regional lymph nodes involved 
Metastasis 
• M1a: Metastasis to one organ 
• M1b: Metastases to more than one organ or peritoneum 
• y: Prefix indicates staging taking place during/following multimodal therapy 
• c: Prefix indicates clinical staging 
• p: Prefix indicates pathological staging    
 
Figure 1: Tumor Node Metastasis standardized staging system (TNM) of rectal cancer 
Adapted from Macgregor, Maughan, and Sharma, (2012) Pathological grading of 
regression following neoadjuvant chemoradiation therapy: the clinical need is now. 
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2.3 Patient Candidacy for treatment 
Before multidisciplinary therapy is recommended, the nature and extent of the 
rectal tumor must be clearly established. Radical surgery comprised of either AR or APR 
is an appropriate treatment option for patients with stage I rectal cancer. With that said, a 
subgroup of T1 tumors may be managed by conservative local excision. Candicacy for 
this procedure is usually reserved for moderately- or well- differentiated T1 tumors, 
without lymphovascular invasion. In addition, the size of the tumor should be less than 3 
cm in diameter and occupying no more than one-third of the circumference of the rectal 
lumen. In contrast, local excision for stage II tumors is controversial, as radical surgery 
has been associated with a lower local recurrence rates for this stage of disease (NCCN, 
2012). For patients with stage II and III rectal cancer (T3–T4 and/or positive lymph 
nodes), neoadjuvant CRT followed by radical surgery is recommended. There are several 
contraindications to performing surgery for the treatment of locally advanced rectal 
cancer. For example, patient comorbidity may preclude surgery regardless of the potential 
to obtain a curative resection. Other factors that contraindicate radical surgery are 
described by Bouchard and Efron (2010), which include circumferential involvement of 
the pelvic sidewall, bilateral ureteric obstruction, tumor encasement of the iliac vessels, 
proximal sacral invasion extending to the sacral promontory, and the extension of tumor 
through the greater sciatic notch. For stage IV cancers, the presence of unresectable 
extrapelvic disease is considered a contraindication for rectal surgery. Furthermore, 
patients who are individually assessed by the surgeon to be a poor surgical candidate 
should not receive multi-modal therapy. 
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2.4 Historical Advances in Rectal Surgery  
Surgery for rectal cancer began in the 18th century. In 1739, Jean Faget of France 
attempted the first rectal excision when he accidently discovered a perforated rectal tumor 
in a patient while draining an ischio-rectal abscess. Unfortunately, the surgery resulted in 
an “uncontrollable sacral anus”, and the patient did not survive (Graney, 1980). In 1826, 
Jacques LisFranc was credited with the first successful rectal surgery. Without the use of 
anesthesia or hemostasis, the patient was asked to bear down while the rectum was turned 
inside out and resected via perineum. At this time, patient outcomes following surgery 
were poor due to complications, which included sepsis, hemorrhage, and recurrent disease 
(Gilbertsen, 1964). In 1874, Theodor Kocher introduced the idea of removing the rectum 
through the sacrum followed by an end-to-end anastomosis of the colon and anus. 
However, perineal and sacral approaches to surgery were eventually deemed inadequate 
due to small surgical fields with no possibility of radical resection and the construction of 
a sacral anus that caused difficulties to the patient. 
In 1879, Carl Gussenbauer performed the first abdominal resection of a proximal 
rectal tumor (Goligher, 1984). This procedure was made possible due to developments in 
the surgical principles of asepsis and both spinal and gas anesthesia. The French surgeon, 
Henri Hartmann, became a strong advocate of abdominal resection because of the 
minimal blood loss associated with the operation. As a result, the surgery was named the 
Hartmann procedure, and it is still performed in both emergency and palliative care 
(Lange, 2009). 
In 1908, William Ernest Miles developed Abdominal Perenial Resection (APR), 
which involves an en bloc removal of tumors occupying the lower one-third of the rectum 
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and their associated lymph nodes. This radical surgery resulted in an abdominal stoma, 
which was more controllable than the sacral anus produced from earlier procedures. 
Furthermore, the recurrence and mortality rate of APR was reported to be 29.5% and 
10%, respectively (Miles, 1923). Despite improvements in these outcomes, APR causes 
permanent colostomy and urogenital dysfunction, which has been shown to impair patient 
quality of life (Sprangers 1995; Kasparek, 2012).  
In 1910, Donald Balfour developed Anterior Resection (AR). This surgery is 
performed through an abdominal approach and incorporates an end-to-end anastomosis, 
leaving the rectal sphincter intact. Initially, this procedure was thought to be insufficiently 
radical (Mayo, 1916). Specifically, critics argued that AR would not fully remove the 
blood supply, lymph nodes and/or adjacent structures of the tumor and as a result, the 
cancer could be given a chance to spread. However, Cuthbert Dukes suggested that the 
downward and lateral spread of rectal cancer was unlikely to occur, as most lymph nodes 
are either parallel or proximal to the level of the tumor (Dukes, 1930). As a result, 
surgeons aimed to perform less radical surgery, while preserving the function of the anal 
sphincter. In 1948, Claude Dixon established the safety of sphincter-preserving surgery, 
when he reported a mortality and 5-year survival rate of 2.6% and 64%, respectively 
(Dixon, 1948). As a result, AR became the standard of care for tumors occupying the 
middle and upper third of the rectum.  
Unfortunately, AR is less likely to be performed for tumors that inhabit the distal 
5-cm of the rectum. During the 1970s, Alan Parks established low AR of the rectum to 
account for these low-lying tumors. This procedure creates an anastomosis between the 
colon and anus, allowing for low-lying tumors to be removed while avoiding colostomy 
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(Parks, 1972). At present, the risk of anastomotic leakage within irradiated fields remains 
high, which requires surgeons to construct diverting ileostomies in most patients (Peeters, 
2005). Still, low colo-anal anastomoses often results in higher rates of stool frequency, 
urgency, and incontinence. As a result, surgeons have produced methods of pouch 
reconstruction, such as the J-pouch and coloplasty (Galler, 2010).  
In addition, sphincter preservation is possible due to the revision of distal margins 
in rectal surgery. Initially, surgeons believed that a 5-cm margin between the resection 
and the distal edge of the tumor was necessary to achieve adequate local control 
(Goligher, 1951). However, studies have reported that distal margins smaller than 2-cm 
do not affect local control or survival for rectal cancer patients (Pollett, 1983, Williams, 
1983). Furthermore, it has been shown that intramural submucosal spread rarely extends 
past 1 cm distally in patients with rectal cancer (kwok, 1996, Andreola, 1997). As a 
result, the National Comprehensive Cancer Network recommends a distal margin of  > 
1cm for patients with low-lying lesions (Nelson, 2001).  
In 1982, William Heald established the principles of TME, which involves an en 
bloc resection of the tumor and the mesorectum to the level of the levator muscles. These 
principles were based on the assumption that rectal tumors spread laterally to the 
mesorectum. Heald noted that both organs were derived from the same tissue and as a 
result, he incorporated sharp dissection of embryologically defined planes into his 
surgical technique. In addition, Heald stressed the importance of a “holy plane” in rectal 
surgery, which he thought should result in the removal of the malignancy, but also the 
preservation of autonomic neural function (Heald, 1982). Hojo and Moriya are credited 
with developing the surgical techniques required to preserve the innervation of urogenital 
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organs (Hojo, 1991; Moriya, 1995). The American surgeon, Warren Enker, combined 
these techniques with the principles with TME in order to increase the rate of sphincter 
preserving surgery (Enker, 1992; Havenga, 2002). However, nerve damage due to rectal 
surgery still remains a major issue (Guren, 2005). 
With the success of neoadjuvant CRT, emphasis has been placed on preserving 
the function of the anal sphincter for patients undergoing rectal surgery (Inoue, 2010). It 
has been hypothesized that neoadjuvant CRT may result in less invasive surgery and 
therefore higher rates of sphincter preservation for patients with locally advanced rectal 
cancer (Marks, 2013).  
 
 
2.5 Adjuvant therapy 
 
2.51 Radiation therapy 
Adjuvant therapy for rectal cancer was implemented into clinical practice during 
the 1980s (Popek, 2011). Prior to this, surgery was often the sole treatment for patients, 
with a survival rate of just 50% (Yorio, 2012; Fisher, 1988; Julien, 2010). The addition of 
radiotherapy, whether administered pre- or postoperatively, has improved the rates of 
local recurrence.  
In 1988, a study by the European Organization for Research and Treatment of 
Cancer found that the addition of neoadjuvant radiation therapy improved both the 5-year 
survival and local recurrence rates of patients with rectal cancer (Gérard, 1988). 
Similarly, the Swedish Rectal Cancer Trial, which compared short-course radiation 
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therapy and surgery with surgery alone found a significant improvement in both local 
recurrence and survival for patients at a median follow up of 13 years. At present, this 
study remains the only randomized trial to have shown a survival benefit for patients with 
locally advanced rectal cancer due to neoadjuvant therapy (Folkesson, 2005). However, 
this experiment began before the introduction of TME, which made it uncertain whether 
the survival benefit was due to radiation therapy or improvements in surgical technique. 
To account for this, the Dutch Rectal Cancer Study Group designed an experiment to 
compare patients treated with radiotherapy and TME verses those who received TME 
alone. Although their results suggested that neoadjuvant radiotherapy decreased the rate 
of local recurrence, no significant benefit to overall survival was observed (Kapiteijn, 
2001). While short course radiotherapy has been shown to induce pathological response 





2.52 Concurrent chemotherapy 
The rationale for giving chemotherapy concurrently with radiotherapy is to 
potentiate local radiotherapy sensitization and as a result, induce tumor down staging. 
Initially, chemotherapeutic agents were introduced as an adjunct to radiotherapy in the 
postoperative setting. Three prospective randomized clinical trials established the 
effectiveness of postoperative chemotherapy in the treatment of rectal cancer. In 1985, the 
Gastrointestinal Tumor Study Group first showed that the combination of chemotherapy 
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and radiotherapy was superior to that of radiotherapy alone. Combination therapy resulted 
in less local recurrence and an increased time to recurrence for patients with locally 
advanced rectal cancer (Gastrointestinal Tumor Study Group, 1985). In 1991, the North 
Central Cancer Treatment Group also evaluated the effects of combining radiotherapy 
with chemotherapy. In comparison to post-operative radiotherapy alone, combination 
treatment was shown to significantly improve patient survival (Krook et al, 1991). 
Furthermore, findings from the National Surgical Adjuvant Breast and Bowel Project 
reported that adjuvant CRT reduced local recurrence, but did not affect overall survival 
for patients (Fisher, 1988). The results of these trials prompted the 1990 U.S. National 
institute of Health consensus conference to recommend postoperative CRT as the 
standard care for patients with stage II and III rectal cancer (NIH, 1990). However, this 
recommendation was premature and highly criticized. For example, the study by the 
Gastrointestinal Tumor Study Group was underpowered and the Krook et al. trial failed to 
significantly reduce the rate of local recurrence (Pasetto, 2004). The lack of evidence for 
postoperative CRT encouraged investigators to examine other treatment modalities. 
More recently, studies have demonstrated the superiority of neoadjuvant CRT. In 
1994, the German Rectal Cancer Study Group initiated a randomized controlled trial to 
compare the long-term efficacy of both neoadjuvant and postoperative CRT. The results 
of the 11-year follow-up showed that neoadjuvant CRT improved local control, and 
resulted in less short- and long-term toxic effects than those who received post-operative 
CRT. Furthermore, neoadjuvant CRT benefited patient compliance and doubled the rate 
of sphincter preservation (Sauer, 2004). The results of this trial had a major influence on 
clinical practice, which now favors neoadjuvant CRT as the standard care for patients 
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with stage II and III rectal cancer. In 2009, Roh et al. reported a higher disease-free 
survival rate and a non-significant trend toward improved overall survival for patients 
who received neoadjuvant CRT (Roh, 2009). Subsequently, a study by Park et al. found 
that neoadjuvant CRT improved sphincter preservation and decreased the risk of surgical 
complication. However, this study found no difference in survival or local recurrence 
between patients who received neoadjuvant and post-operative CRT (Park, 2011).  
Furthermore, a recent study by Lee et al. showed neoadjuvant CRT to be superior to 
postoperative CRT in terms of tumor down-staging and sphincter preservation (Lee, 
2013).  At present, most studies suggest that neoadjuvant CRT has a greater benefit to 
local control, toxicity, patient compliance, and sphincter preservation. However, no 




2.6 Recurrent disease 
The probability of a patient with recurrent rectal cancer surviving five years is less 
than 7%, with a mean life expectancy of just 7 months (McCarthy, 2012). As a result, a 
main goal of treatment is preventing both local and distant recurrence of rectal cancers 
following definitive surgery. Local recurrences refer to any tumor that recurs in the true 
pelvis, which includes the neorectum, mesentery, pelvic viscera, pelvic sidewall 
structures, and bone (Yeo, 2013). According to the IUCC, the term local recurrence can 
only be applied if a complete resection is achieved, leaving no macroscopic evidence of 
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tumor locally (Heriot, 2006). Cancer cells that are neither destroyed by CRT nor removed 
from surgery may act as seed cells for local recurrence (Peng, 2013). 
The Memorial Sloan Kettering group describes a classification system of local 
recurrence based on their anatomical region of the pelvis. For example, axial recurrences 
were subdivided into anastomotic, residual mesorectum, or perirectal soft tissue of the 
pelvis and perineum. The term anterior describes recurrences of the genitourinary tract, 
while posterior involves the sacrum, presacral fascia or sacral root sheaths. Lastly, lateral 
recurrences involve the muscles and soft tissue of the pelvic sidewall, lymph nodes, major 
iliac vessels, sacral nerve plexis, and lateral bony pelvis (Guillem, 2008). The Dutch 
TME trial group used a similar classification of local recurrence, but separated 
anastomotic and perineum recurrences (Kusters, 2010).  
A diagnosis of local recurrence is usually made by either one of the following 
major criteria: (1) histological confirmation, (2) palpable or evident disease with 
subsequent clinical progress, (3) evidence of bone destruction, or (4) positron emission 
tomography examination, and one of the following minor criteria: (1) gradual 
enlargement of mass with repeated CT or MRI scans, (2) invasion of nearby tissues, (3) a 
rise in the levels of tumor markers, and (4) findings made with endoscopic ultra sound, 
CT, or MRI (Enriquez-Navascues, 2011). The majority of local recurrences occur within 
2 - 3 years following definitive surgery and approximately 33% of which can be resected 
(Palmer, 2007; Bakx, 2008). In the 1980s, Heald and Ryall introduced TME, based on the 
premise that primary rectal tumors have a tendency to spread laterally to the mesorectum 
(Heald, 1982; Heald 1986). The mesorectum is a fatty connective tissue layer that 
surrounds the rectum and contains blood vessels, lymphatics, and lymph nodes (Parfitt, 
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2007). As they predicted, removal of the mesorectal tissue successfully reduced the 5-
year rate of local recurrence from 30 - 40% to < 10 % (Glimelius, 2013,Wibe 2003; 
MacFarlane, 1993; Enker, 1995).  
Approximately 20-30% of patients with rectal cancer have a distant recurrence 
following surgery, with the most common sites being the liver and lungs (Arredondo, 
2015). To date, neoadjuvant therapy has added little benefit in terms of managing 
metastatic disease (Ding, 2012). However, adjuvant therapy has been incorporated into 
practice in order to better prevent distant recurrences. Following neoadjuvant therapy and 
surgery, the patient often receives adjuvant therapy, which consists of chemotherapy for 4 
– 6 months. Similar to the role of neoadjuvant therapy in reducing local failures, this 
postoperative treatment is given systemically to prevent distally recurrent disease 
(Berardi, 2014). This recommendation is made largely based on the results of a 2004 
meta-analysis by Gunderson et al., which demonstrated a 20% survival benefit for 
patients receiving postoperative chemotherapy in comparison to those receiving 
postoperative radiation therapy (Gunderson, 2004). Still, some investigators do not agree 
with this practice, as most locally advanced rectal cancers are node negative following 
neoadjuvant therapy (Park, 2014). Although the presence of metastatic disease 
dramatically reduces the chance of survival, the number of distant recurrences treated 
with curative intent is increasing (Ding, 2012; Tjandra, 2007). Repeat surgical resection 
may be possible for certain patients, whereas others may avail of two-stage hepatectomy, 
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2.7 Prognostic factors 
 
2.71 Surgical margins 
The choice of surgical technique is largely dependent on the potential for 
achieving a curative or “R0” resection, which refers to the complete excision of the 
tumor, leaving no residual disease. Obtaining an R0 resection dramatically reduces the 
rate of disease recurrence and is an important determinant of patient survival (Martling, 
2004; Hahnloser, 2003). In order to achieve a R0 resection, both the distal and the 
circumferential surgical margins must be uninvolved by tumor. 
Approximately 10% of rectal cancer cases exhibit intramural extension below the 
level of the tumor, which describes the need for adequate distal margins in rectal surgery 
(Mezhir, 2012; Shimada, 2011). The distal margin refers to the amount of clearance 
allowed between the distal edge of the tumor and the resection. Given that intramural 
tumor extension rarely exceeds 1 cm distally, a margin of ≥1 cm is generally 
recommended for patients undergoing AR (Shirouzu, 2009; Guillem, 2007). Moreover, 
distal margins that exceed 1 cm tend to have no added benefit in terms of disease-free 
survival (Pahlman, 2013; Moore, 2003). Occasionally, this recommendation is violated 
for patients who have received neoadjuvant CRT (Silberfein, 2010; Nash, 2010).  In this 
case, neoadjuvant therapy may cause regression of microscopic disease, allowing for 
smaller margins in patients who would otherwise need permanent colostomy (Bujko, 
2012). The distal margin is measured in vivo or by pinning the specimen to a board 
immediately following surgery (Shirouzu, 2009).  
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The Circumferential Resection Margin (CRM), also known as the radial margin, is 
arguably the most important risk factor for local recurrence after radical surgery (Wibe, 
2012; Nagtegaal, 2002). CRM refers to the shortest distance between the edge of the 
tumor and the mesorectal fascia (Monson, 2013). A CRM that is within 1 mm of the 
primary tumor is considered to be a positive margin and this result is associated with an 
increased risk of both local and distant recurrence, and worsened survival (Kennelly, 
2013, Nagtegaal, 2008). In 1986, Quirke et al. first observed that 85% of patients with a 
positive CRM developed local recurrence, compared with only 3% of those who had 
uninvolved margins (Quirke, 1986). Similarly, the results of a large Dutch trial found that 
patients with a positive CRM had a local recurrence rate of 22%, in comparison to 4% of 
patients with negative margins (Peeters, 2007). Achieving a clear CRM with the removal 
of the rectal tumor should largely eliminate the risk of local recurrence (Taylor, 2013). 
 
2.72 Presence of lymphovascular and perineural invasion 
Nodal involvement has been shown to accurately predict local recurrence (Kim, 
2009). Historically, local recurrence rates were as high as 20 – 40%, likely because of 
failure to remove positive lymph nodes in the mesorectum and pelvic sidewall during 
surgery (Simunovic, 2008). Halsted et al. was among the first to suggest that tumor cells 
spread from the primary tumor to regional lymph nodes and as a result, radical surgery 
would decrease the rate of local recurrence (Halsted, 1894). Similarly, William Ernest 
Miles stressed the importance of removing the regional lymphatics during surgery 
following his post-mortem examinations of patients that revealed recurrence in the lymph 
nodes surrounding the left common iliac artery. The results of a study conducted by 
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Miholic et al. suggested nodal involvement to be a stage-independent risk factor for local 
recurrence (Miholic, 1991). Similarly, Elferink et al, found that patients with positive 
lymph nodes were more likely to develop locoregional recurrence in comparison to those 
without positive lymph nodes (Elferink, 2012).  
In addition, vascular invasion is a stage-independent risk factor for local 
recurrence (Bhangu, 2013). Vascular invasion refers to the presence of malignant cells 
within the blood vessels of the rectum and is associated with locally advanced tumors 
(Smith, 2008).  In 1938, Brown and Warren were credited with identifying vascular 
invasion as a risk factor for local recurrence. Their post-mortem study of 170 patients 
with rectal cancer revealed visceral metastases in 71% of those cases positive for vascular 
invasion. More recently, several other studies have suggested that patients, who have 
extramural venous invasion, are more likely than patients without venous invasion to 
develop locally recurrent rectal cancer (Megaurditchian, 2005; Dresen, 2009).  
Perineural invasion occurs when the tumor invades and spreads via the nervous 
system. Although there is no agreed upon definition of perineural invasion, Batsakis et al. 
coined a broad and widely used description of perineural invasion in 1985, stating it as 
“invasion of the cancer in, around, and through the nerves” (Batsakis, 1985). Historically, 
perineural invasion has been an important prognostic factor in head and neck, prostate, 
pancreas, colon, and skin cancers. More recently, it has been established as a predictor for 
adverse outcomes in patients with locally advanced rectal cancer, who are receiving 
neoadjuvant therapy. Still, the rate of identification is below 31%, as it is an 
underreported measure. Perineural invasion has been shown to negatively impact disease-
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free survival, local-recurrence free survival and overall survival (Kim, 2009; Dhadda, 
2014; Chablani, 2015).  
 
 
2.73 Histological grade of tumor 
Tumor grading refers to the assessment of cellular appearance within cancerous 
tissue and it is another important prognostic factor in the treatment of CRC. According to 
categorization from the World Health Organization, the primary consideration for tumor 
grading is gland formation. As a result, signet ring, small cell, and undifferentiated 
carcinoma types are all classified as poorly differentiated (Hav, 2015). For 
adenocarcinomas of the rectum, this tumor grading is largely subjective, leading to inter-
observer variability. In addition, numerous grading schemes with different criteria exist in 
the literature, further complicating this prognostic factor. With that said, grading remains 
a stage independent prognostic factor in the non-neoadjuvant setting. However, results 
from randomized controlled trials question its predictive ability of overall survival 
(Rullier, 2010; Sprenger, 2010). Most grading schemes separate tumors into 1 of 4 
groups: well differentiated, moderately differentiated, poorly differentiated, and 
undifferentiated. In terms of risk stratification, a high tumor grade, signifying poor 
differentiation, indicates an aggressive form of the disease and a worsened chance of 
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2.8 Mortality 
 During the past 30 years, survival rates of patients with locally advanced rectal 
cancer have significantly improved due to advancements in surgical technique and 
adjuvant therapy (Inoue, 2010). Prior to the introduction of adjuvant therapies, the 5-year 
overall survival rate was approximately 50% (Yorio, 2012; Julien, 2010).  At present, 5-
year overall survival for locally advanced rectal cancer is approaching 71% (ASCO, 
2020; American Cancer Society, 2020). Although neoadjuvant therapy has successfully 
lowered the rate of local recurrence for patients with locally advanced rectal cancer, 
historically, it is thought to have no significant effect on patient survival (Kapiteijn, 2001, 
Sauer, 2004). The Swedish rectal cancer study, which began in 1997, was the first trial to 
suggest an improvement in overall survival due to neoadjuvant therapy. At this time, this 
result was largely attributed to non-standardized surgery, which did not include the 
principles of TME.  To account for this, the Dutch Colorectal Cancer Study Group 
published a paper in 2001, which standardized surgical intervention between patients. The 
result of their trial showed no difference in the 5-year overall survival rate between 
groups that received either surgery alone or surgery with neoadjuvant short-course 
radiation (Kapiteijn, 2001). Similarly, the German Rectal Cancer Study Group’s 2004 
seminal paper reported no significant difference in 5-year overall survival between 
neoadjuvant and postoperative CRT groups (Sauer, 2004).  In 2007, Cambray i Amenos 
et al. achieved the same result, as no difference in overall survival could be observed 
between groups receiving neoadjuvant and postoperative therapies (Cambray i Amenos, 
2007).  
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In 2009, Sebag-Montefore et al. compared the effects of neoadjuvant radiation 
therapy verses post-operative CRT in terms of overall survival. Again, no significant 
association was found between neoadjuvant therapy and overall survival (Sebag-
Montefore, 2009). However, a study by Roh et al. was published during that same year, 
suggesting a non-significant trend in overall survival for patients who had received 
neoadjuvant therapy. In 2012, Kang et al. demonstrated an association between 
neoadjuvant therapy and improved overall survival, specifically for patients with stage III 
rectal cancer (Kang, 2012). More recently, Tural et al. published a study that found no 
association between neoadjuvant therapy and overall survival (Tural, 2013). 
Some investigators have begun to retrospectively analyze data collected from 
cohorts of patients over the past two decades in order to determine how the change in 
CRT practice has affected patient survival. In 2014, Wiegering et al. compared overall 
survival between patients receiving treatment over the past two decades. They found that 
patients, who were treated after 2002, had a significantly improved 5-year survival rate in 
comparison to patients in the earlier cohort (Wiegering,. 2014). However, a similar study 
by Zengel et al. showed no difference in overall survival between patients treated before 
and after 2004 (Zengel, 2015). Interestingly, Law et al. published a study this year 
comparing two cohorts of patients with locally advanced rectal cancer receiving surgery 
between either 1993 – 2001 or 2002 – 2011. The investigators observed a lower 
recurrence rate and a higher survival rate in the more recent cohort, which incorporated 
neoadjuvant therapy and laparoscopic surgery (Law, 2016). At present, it remains unclear 
whether an association between neoadjuvant CRT and overall survival exists. 
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Summary of Literature Review 
At present, an extensive amount of research exists regarding the treatment of 
locally advanced rectal cancer. Routine management remains a multidisciplinary effort, 
consisting of diagnosis, staging, adjuvant therapy, and surgical resection. Historically, the 
main burden of rectal cancer was a high risk of locally recurrent disease. However, 
neoadjuvant therapy has reduced the rate of local failure to < 10%, while adding no 
benefit to managing distant recurrences. As a result, metastatic disease now presents the 
next challenge to improving patient survival. At present, it remains unclear whether 
neoadjuvant CRT benefits overall survival in comparison to therapy administered 
postoperatively. Specifically, only one randomized controlled trial to date has suggested 
neoadjuvant therapy results in improved survival. However, this result is largely 
attributed to the effects of unstandardized surgery. More recently, retrospective cohort 
studies have suggested that neoadjuvant therapy may offer a survival benefit (Roh, 2009; 
Kang, 2012; Wiegering, 2014; Law, 2016). Still, other studies refute these findings 
(Sebag-Montefore , 2009; Cambray, 2007; Tural, 2013; Park, 2011; Sauer, 2012; 
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Chapter 2: METHOD 
 
3.1 Study Approval 
Approval to conduct this study was granted by the Health Research Ethics Board 
of the Faculty of Medicine, Memorial University of Newfoundland (Appendix A) in 




In the province of Newfoundland & Labrador, retrolective chart audits were 
conducted on all incident cases of rectal cancer diagnosed between January 4th, 1999, and 
December 15th, 2003 in patients aged 20 – 74 years. The Newfoundland & Labrador 
Colorectal Cancer Registry (NFCCR) is a population-based registry that has collected 
information on all patients diagnosed with CRC, aged 20 – 74 years old. Each patient was 
given an International Classification of Diseases code to indicate colon (153) or rectal 
(154) cancer by the Newfoundland Cancer Treatment and Research Centre. In addition, a 
hospital based staff pathologist reviewed each pathology report to confirm a correct 
diagnosis of adenocarcinoma or its subtypes: mucinous or signet ring cell carcinoma. 
Information letters were sent via mail to the attending physicians of all patients with a 
diagnosis of rectal cancer (154). This letter described the study and provided contact 
information for those who were interested in participating. The next of kin was identified 
by contacting family physicians and nursing clinics in the circumstances that the patient 
was either deceased or alive with a preference for next of kin (proxy) contact. Each next 
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of kin was contacted using the original method as the patient themselves and was asked to 
consent to a review of the affected family member’s medical charts (proxy consent). 
Consent was given by the patient or next of kin to abstract information from the patients’ 
medical records regarding the diagnosis, treatment, and prognostic variables related to 
their cancer care. Recruitment occurred at a later date in the NFCCR cohort in 
comparison to other cohorts and as a result, proxy consent was used throughout given 
many of the patients has already passed. 
Similarly, chart reviews were performed for patients enrolled in the Ontario 
Familial Colorectal Cancer Registry (OFCCR). The OFCCR is a National Cancer 
Institute consortium that promotes the genetic and epidemilological study of CRC. 
Furthermore, this registry is 1 of 6 international sites that contribute to the Cooperative 
Familial Registry for Colorectal Studies (Wirtzfeld, 2009). Since 1997, the OFCCR has 
collected family history information, epidemiological data, blood samples, and tumour 
tissue from a population-based sample of patients (probands) with CRC and their families 
(Cotterchio, 2000). The population-based Ontario Cancer Registry was used to identify all 
cases of rectal cancer that were diagnosed between July 3, 1997, and June 23, 2000, 
among residents of Ontario aged 18– 74 years. Patients were recruited into the OFCCR 
based on their familial risk of developing CRC. All patients that have high or moderate 
risk are selected to participate in the OFCCR, and an additional 25% of the sample is 
randomly selected from patients at low risk of developing CRC. Consent was given in 
order to extract information from the patients’ medical records regarding their diagnosis 
and treatment. Proxy consent was not sought for the Ontario sample. 
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In addition, data from a third cohort of patients with rectal cancer was obtained 
from the health records of a surgeon’s single practice in Newfoundland & Labrador. A 
retrospective chart review was conducted on all of this surgeon’s patients diagnosed 
between January 1st, 1992, and April 16th, 2014, aged 22 - 97 years. Information 
regarding patient mortality and date of death obtained from the surgeon’s files was cross-
referenced with the patient’s records abstracted from the H. Bliss Murphy Cancer Center. 
If there was a discrepancy in mortality between the two patient records, then information 
from the H. Bliss Murphy Center was preferentially included. In terms of recurrent 
disease, every case of local recurrence was reviewed by the surgeon of the single practice 
to improve validity. If cases of distant recurrence varied between the two patient records, 
then the files of those participants were again reviewed by the surgeon. Any patient of the 
single practice cohort that was also a patient in the NFCCR was excluded from the single 
practice cohort to prevent duplicate cases. Cases were also excluded from the single 
practice cohort if the patient was identified as receiving palliative management, if a local 
excision was performed prior to radical surgery, or if the patient had no operation 
completed. Consent was given for the investigators of this study to review the charts of 
each patient and information was collected by two medical students, using the same 
abstraction form as mentioned previously.  
 
 
3.3 Data Collection 
This was a retrolective cohort study of patients with rectal cancer, who received 
treatment before the beginning of our study. Subsequently, the existing charts of these 
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patients were retrospectively reviewed and data obtained from each patient’s file was 
recorded in our dataset. This patient information was updated prospectively at appropriate 
follow up visits. Trained Health Record Technicians and Research Nurses reviewed and 
abstracted each patient’s medical records. The standardized abstraction form (Appendix 
B) included information on patient demographics, diagnosis (symptoms, location of 
diagnosis, site of cancer and date of diagnosis), surgical intervention (date, type of 
surgery, operative findings, hospital/surgeon), pathology (stage, number of lymph nodes, 
tumor differentiation/cell type, microscopic margins confirmed by pathologist, 
perineural/lymphovascular invasion), adjuvant treatment (start date, type of 
chemotherapy), follow-up (first documented loco-regional and/or distant recurrence and 
treatment for recurrence), time to last follow up, and/or death and cause of death. In 
addition, approximately 50% of the charts were randomly selected and reviewed by two 
physician researchers to ensure the data entered in the dataset was correct. 
 
 
3.4 Statistical Analysis 
Patients were separated into 1 of 3 cohorts: the NFCCR from 1999 – 2003, the 
OFCCR from 1997 - 2000, and the single practice of a colorectal surgeon working in 
Newfoundland and Labrador from 1993 - 2014. The primary outcome of our study was 
overall survival, which was measured from date of diagnosis to the date of death or the 
date of last follow-up, if death had not yet been documented. A secondary outcome of this 
study was local recurrence-free time to event, which was measured from date of diagnosis 
to the diagnosis of a recurrence, localized to the true pelvis, or to the date of last follow-
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up. Another secondary outcome was disease-free time to event, which was measured from 
date of diagnosis to the date of recurrence outside of the true pelvis, or to the date of last 
follow-up. 
 
• Descriptive statistics were performed to determine if there were significant 
differences between the three cohorts at baseline. Categorical variables were 
analyzed and presented as n (%) using chi square (χ²) analysis to ascertain 
possible confounding factors. The only continuous variable analyzed was age, 
which was compared between the cohorts by using the one-way analysis of 
variance (ANOVA) test. In addition, the three main study outcomes:  
o Overall survival,  
o local recurrence-free time to event,  
o and disease-free time to event, 
 
were compared among cohorts using the log-rank test and presented using 
Kaplan-Meier survival curves. Univariate analysis was performed to determine the 
prognostic effect of each predictor on overall survival, local recurrence-free time 
to event and disease-free time to event. Multivariate cox regression models were 
performed on overall survival, local recurrence-free time to event and disease-free 
time to event to evaluate the effect of neoadjuvant therapy independent of 
potential confounding variables. 
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Chapter 4: RESULTS 
 
4.1 Description of study sample  
From 1993 to 2014, a total of 757 patients with rectal cancer were recruited from 
the NFCCR, the OFCCR, and the single practice of a colorectal surgeon in 
Newfoundland. Of these, 27.5% (208) of participants came from the NFCCR, 36.5% 
(276) came from the OFCCR, and another 36.1% (273) came from the records of the 
colorectal surgeon’s single practice. Given that this is a non-randomized trial, the SPSS 
23 computer program was used to investigate potential differences at baseline between 
each of the three cohorts. Pearson chi-square tests were performed to investigate patient 
factors, such as gender, cell type, neoadjuvant therapy, surgery type, staging, surgical 
margins, tumor grade, and presence of invasion. For the continuous variable, age, a non-
parametric Kruskal-Wallis test was performed to assess differences between the three 
cohorts. 
Table 1 shows the baseline differences between the NFCCR, the OFCCR, and the 
patients of the surgeon’s single practice. As depicted in the table, no statistically 
significant difference exists between the three cohorts in terms of age, rates of APR, rates 
of locally advanced and advanced cancers, and the rate of poorly differentiated disease. In 
contrast, there was a significant difference in regards to male gender between the three 
cohorts, with the OFCCR having fewer males than both the NFCCR and the single 
practice (60% vs. 69% vs. 70%, respectively; p-value = 0.018). In addition, there was a 
baseline difference between the numbers of rectal adenocarcinomas between the three 
cohorts, with the patients of the single practice having a significantly lower rate of 
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adenocarcinomas (81% vs. 89% vs. 87%, single practice vs. NFCCR & OFCCR, 
respectively). As hypothesized, there are an increased proportion of patients treated with 
neoadjuvant therapy in the single practice cohort, as this is the only group with patients 
diagnosed after 2004 (27% vs. 4% vs. 8%; single practice vs. NFCCR vs. OFCCR, 
respectively). This result reflects the widespread acceptance of neoadjuvant therapy as 
standard practice following the publication of Sauer’s seminal paper. Similarly, there is a 
higher rate of AR in the surgeon’s single practice cohort than either registry’s data (68% 
vs. 54% vs. 47%; Single practice vs. NFCCR vs. OFCCR, respectively). 
 The only baseline difference in terms of staging can be seen among stage I 
disease in the OFCCR cohort. The OFCCR has an increased rate of localized cancers in 
comparison to the NFCCR and the OFCCR, respectively (33% vs. 18% vs. 25%). This 
effect can be partly explained by the absence of proxy consent in the recruitment of 
OFCCR’s participants, resulting in a higher proportion of earlier staged cancers. In 
addition, there was a significantly lower rate of completely excised tumors for patients in 
the single practice cohort (85% vs. 90% vs. 93%; Single practice vs. NFCCR vs. OFCCR, 
respectively). In terms of tumor grade, the single practice cohort had a significantly 
higher percentage of well-differentiated cancers than both the NFCCR and the OFCCR, 
respectively (16% vs. 10% vs. 10%). Similarly, the single practice had a lower proportion 
of moderately differentiated cancers (56% vs. 78% vs. 74%; single practice vs. NFCCR 
vs. OFCCR, respectively). The presence of vascular, lymphatic, and perineural invasion 
was statistically different between the three cohorts. The NFCCR had a significantly 
higher rate of vascular invasion than both the OFCCR and the single practice (33% vs. 
11% vs. 17%, respectively). Similarly, the NFCCR had an increased proportion of 
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lymphatic invasion (34% vs. 12% vs. 23%; NFCCR vs. OFCCR vs. single practice, 
respectively) and perineural invasion (27% vs. 4% vs. 14%; NFCCR vs. OFCCR vs. 




Table 1: Baseline clinical & pathological characteristics of cohorts 
 
 
Total& NFCCR OFCCR Single&practice P&5&value
n 757 208 276 273
Age;&median&(SD) 61)(10) 61)(9) 61)(10) 62)(12) NS
Male&gender;&n&(%) 501)(66) 144)(69) 165)(60) 192)(70) 0.018
Cell5type;&n&(%)
Adenoncarcinoma,&NOS;&n&(%) 646)(85) 185)(89) 240)(87) 221)(81) 0.041
Neo5adjuvant&therapy;&n&(%) 103)(14) 9)(4) 21)(8) 73)(27) <)0.001
Type&of&surgery&performed;&n&(%)
Anterior&resection;&n&(%) 428)(57) 112)(54) 130)(47) 186)(68) <)0.001
Abdominoperineal&resection;&n&(%) 211)(28) 69)(33) 79)(29) 63)(23) NS
Pathological&staging&(pTNM);&n&(%)
Stage&1;&n&(%) 194)(26) 37)(18) 90)(33) 67)(25) 0.001
Stage&2;&n&(%) 213)(28) 68)(33) 74)(27) 71)(26) NS
Stage&3;&n&(%) 275)(36) 80)(39) 89)(32) 106)(39) NS
Stage&4;&n&(%) 62)(8) 23)(11) 21)(8) 18)(7) NS
Tumor&entirely&resected;&n&(%) 676)(89) 188)(90) 256)(93) 232)(85) 0.002
Grade&of&primary&tumor
Well&differentiated;&n&(%) 93)(12) 21)(10) 27)(10) 45)(16) 0.01
Moderately&differentiated&;&n&(%) 519)(69) 163)(78) 204)(74) 152)(56) <)0.001
Poorly&differentiated;&n&(%) 80)(11) 21)(10) 27)(10) 32)(12) NS
Presence&of&invasion;&n&(%)
Vascular&invasion;&n&(%) 145)(19) 69)(33) 29)(11) 47)(17) <)0.001
Lymphatic&invasion;&n&(%) 169)(22) 71)(34) 34)(12) 64)(23) <)0.001
Perineural&invasion;&n&(%) 106)(14) 57)(27) 10)(4) 39)(14) <)0.001
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4.2 Outcome measurements by patient cohort  
Table 2 shows the overall survival among the three cohorts recorded at 2, 4, 6, 8, 
and 10-years of follow up. The three cohorts of patients were compared in order to 
determine if there was a statistical difference in the average time between cancer 
diagnosis and the date of all-cause mortality. There was no significant difference in 
survival rate between any of the three cohorts ((log rank (mantel-cox) = 3.992; p-value = 
0.136). The median survival for the NFCCR, the OFCCR, and the single practice was 
90.7 months, 107.6 months, and 97.3 months respectively, with all three confidence 
intervals overlapping. 
 






 Figure 2 shows these same survival rates in graphical representation. As depicted 
by the graph, the survival curves of the 3 cohorts overlap, suggesting that there is no 
Cohort	 N N	 Survival	 Median	suvival	 95%	CI
of	events (%	alive	at	follow-up) 	(months)
2	years 4	years 6	years 8	years 10	years
NFCCR 208 100 87.5 70.7 60 49.4 23 90.74 (72.594,	108.886	)
OFCCR 274 110 94.5 80.5 70.6 59.3 37.6 107.605 (94.210,	121.001	)
Single	practice 262 89 85.5 70.2 56.6 50.6 45.5 97.315 (59.534,	135.096)
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statistical difference in the time between cancer diagnosis and all-cause mortality for any 




Log rank (Mantel-Cox) = 3.992; df=2; p = 0.136 
 
 




Table 3 shows the local recurrence-free time to event for each cohort at 2, 4, 6, 8, 
and 10 years of follow up. Each cohort was compared in order to determine if there was a 
statistical difference between the average local recurrence-free time to event, measured 
from date of diagnosis to date of local recurrence, or if not applicable, the date of last 
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follow-up. Patients of the OFCCR experienced a significantly improved local recurrence-
free time to event in comparison to both the NFCCR and the single practice cohort (log 
rank (mantel-cox) = 15.783; p-value < 0.001). Given that the time to event rate never 
reached 50% over 10 years for either cohort, median time to event estimates were not 
calculated. From the table, one can tell that the time to local recurrence event was 
significantly improved for patients of the OFCCR, as 93.3% of patients were without 
local recurrence at 10 years in comparison to 79% and 86.9% of the patients in the 
OFCCR and NFCCR, respectively. 
 







Figure 3 shows the Kaplan-Meier curve of local recurrence-free time to event for 
the NFCCR, the OFCCR, and the single practice cohorts. As shown by the graph, the 
local recurrence-free time to event for patients in the OFCCR cohort is significantly better 
than both the NFCCR and the single practice. Given that the OFCCR did not incorporate 
proxy consent into the recruitment of participants, the improved local recurrence-free 
Cohort	 N N	 Time	to	event	
of	events (%	with	no	event	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 205 33 92.3 85 84.3 79 79
OFCCR 274 15 97 95 95 93.3 93.3
Single	practice 260 23 91.6 88.2 86.9 86.9 86.9
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time to event may be partially explained by not recruiting these patients with more 
advanced stages of disease and worse prognosis. As a result, an increased proportion of 





Log (Mantel-Cox) = 15.783; df = 2; p < 0.001 
 
 
Figure 3: Kaplan-Meier curves of local recurrence-free time to event by patient 
cohort for patients of all stages 
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Table 4 shows the disease-free time to event for each of the three cohorts at 2, 4, 
6, 8, and 10 years of follow up. Each cohort was compared in order to determine if there 
was a statistical difference between average disease-free time to event, measured from the 
date of primary cancer diagnosis to the date of disease recurrence, whether it be local or 
distant spread. If the patient did not experience either local or distant disease recurrence, 
then the date of last follow-up was used instead. Patients of the OFCCR experienced a 
significantly improved disease-free time to event in comparison to both the NFCCR and 
the single practice cohorts (log rank (mantel-cox) = 19.357; p-value < 0.001). Given that 
the disease-free recurrence curves for the OFCCR and single practice cohorts did not 
reach 50%, median time to event estimates were not calculated. At 10 years, the 
proportion of patients without recurrent disease for the NFCCR, OFCCR, and the single 
practice was 48.6%, 74.2%, and 62.1%, respectively.  
 




Cohort	 N N	 Time	to	event	
of	events (%	with	no	event	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 192 82 75.9 62.3 57.8 54.2 48.6
OFCCR 274 65 88.1 78.1 75.6 74.2 74.2
Single	practice 257 63 79.8 67.1 63.6 62.1 62.1
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Figure 4 shows the disease-free recurrence curves for the NFCCR, the OFCCR, 
and the single practice cohorts. As depicted by the figure, the OFCCR time to event 
estimates are significantly improved, as the curve does not overlap that of any other 
cohort. Again, this can likely be explained by the absence of proxy consent during the 





Log (Mantel-Cox) = 19.161; df = 2; p < 0.001 
 
Figure 4: Kaplan-Meier curves of disease-free time to event by patient cohort for 
patients of all stages 
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4.3 Univariate predictors of survival and of recurrence 
Table 5 shows the results of the univariate analysis of overall survival for the 
patients of the three cohorts. Age at diagnosis was found to be a significant predictor of 
overall survival. For each year of age, the risk of patient mortality increases by 2.6% 
(1.014 – 1.038; p < 0.001). In addition, a significant association was found between sex 
and overall survival, as male patients had a 36% higher chance of death than their female 
counterparts (1.057 – 1.748; p = 0.015). No significant association was found between 
neoadjuvant therapy and overall survival. Similarly, cell type had no effect on overall 
survival. AR surgery was associated with a 38% risk reduction in mortality (0.497 – 
0.784; p < 0.001). Other significant predictors of overall survival include complete 
excision, tumor grade, vascular, lymphatic, and perineural invasion. As expected, later 
stages of cancer were associated with an increased risk of all-cause mortality, as patients 
with stage IV cancers were 9.5 times more likely to experience mortality in comparison to 
patients with stage I disease (6.371 – 14.289; p < 0.001). In terms of cohort, patients of 
the OFCCR had a 24% reduced risk of all-cause mortality in comparison to the NFCCR 
(0.579 – 0.996; p = 0.046). Again, this may be attributed to the fact that the OFCCR did 
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Table 6 shows the results of the univariate analysis of local-recurrence free time to 
event for patients of the three cohorts. The adenocarcinoma cell type was found to be a 
significant predictor of local recurrence. Specifically, the presence of this pathology was 
associated with a 49% reduced risk of developing local recurrence (0.289 – 0.882; p = 
0.016). No significant association was found between neoadjuvant CRT and the 
development of local recurrence. Complete excision of the tumor was associated with a 
52% risk reduction of local recurrence (0.237 – 0.965; p = 0.039). As shown in table 6, 
predictors of poor prognosis included poorly differentiated grade, and the presence of 
vascular, lymphatic, and perineural invasion. In regards to stage of the disease, stage II 
n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 744	(100) 1.026 1.014	-	1.038 <	0.001
Male	Sex 493(66) 1.36 1.057	-	1.748 0.015
Adenocarcinoma,	NOS	 637	(86) 0.755 0.555	-1.027 NS
Neoadjuvant	therapy	 103	(14) 1.097 0.777	-	1.549 NS
Anterior	resection 428	(58) 0.624 0.497	-	0.784 <	0.001
Tumor	completely	excised 669	(90) 0.343 0.245	-	0.480 <	0.001
Grade	of	tumor,	poorly	differentiated 80	(11) 2.124 1.538	-	2.934 <	0.001
Vascular	invasion 145	(19) 2.025 1.572	-	2.608 <	0.001
Lymphatic	invasion 169	(23) 1.748 1.368	-	2.235 <	0.001
Perineural	invasion 106	(14) 2.314 1.754	-	3.053 <	0.001
Stage
I	 194	(26) 1
II 213	(29) 1.857 1.282	-	2.689 0.001
III 275	(37) 2.538 1.803	-	3.573 <	0.001
IV 62	(8) 9.541 6.371	-	14.289 <	0.001
Cohort
NFCCR 208	(28) 1
OFCCR 274	(37) 0.759 0.579	-	0.996 0.046
Single	practice 262	(35) 0.867 0.641	-	1.172 NS
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and III rectal cancers were found to multiply the risk of local recurrence by 2.3 times 
(1.043 – 4.974; p = 0.039) and 3.5 times (1.685 – 7.215; p = 0.001), respectively. Lastly, 
cohort was found to have a significant effect on the risk of local recurrence. Specifically, 
patients of the OFCCR cohort were found to have a 24% risk reduction in developing 
locally recurrent disease. 
 
Table 6: Results for univariate analysis of local recurrence-free time to event for 







n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 744	(100) 1.006 0.983	-	1.030 NS
Male	Sex 489	(66) 1.019 0.626	-	1.658 NS
Adenocarcinoma,	NOS	 633	(85) 0.505 0.289	-	0.882 0.016
Neoadjuvant	therapy	 103	(14) 0.927 0.444	-	1.936 NS
Anterior	resection 426	(57) 0.677 0.425	-	1.078 NS
Tumor	completely	excised 666	(90) 0.478 0.237	-	0.965 0.039
Grade	of	tumor,	poorly	differentiated 80	(11) 3.068 1.753	-	5.368 <	0.001
Vascular	invasion 143	(19) 2.685 1.649	-	4.371 <	0.001
Lymphatic	invasion 167	(22) 2.276 1.404	-	3.689 0.001
Perineural	invasion 105	(14) 1.946 1.100	-	3.444 0.022
Stage
I	 193	(26) 1
II 212	(28) 2.278 1.043	-	4.974 0.039
III 273	(37) 3.487 1.685	-	7.215 0.001
IV 61	(8) 1.968 0.531	-	7.297 NS
Cohort
NFCCR 205	(28) 1
OFCCR 274	(37) 0.309 0.168	-	0.568 <	0.001
Single	practice 260	(35) 0.754 0.442	-	1.287 NS
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Table 7 shows the results of the univariate analysis of local-recurrence free time to 
event for patients of the three cohorts. Male sex was found to increase the risk of disease 
recurrence by 46% (1.078 – 1.969; p = 0.014). AR surgery and complete excision were 
associated with a 28% (0.547 – 0.940; p = 0.016) and and 39% (0.387 – 0.956; p = 0.031) 
risk reduction of disease recurrence, respectively. Similar to local recurrence-free time to 
event, poorly differentiated cancers and the presence of vascular, lymphatic, and 
perineural invasion were all significantly associated with increased risk of disease 
recurrence. In regards to stage of the disease, patients with stage II disease were 1.9 times 
(1.170 – 2.943; p = 0.009) more likely to develop local recurrence, patients with stage III 
disease were 3.7 times more likely to develop local recurrence, and those with stage IV 
disease were 5.2 times more likely to develop local recurrence than stage I patients, 
respectively. Again, the OFCCR cohort was associated with a 51% reduced risk of 
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4.4 Multivariate models of survival and disease recurrence  
Subsequently, a multivariate model was constructed to determine the effect of 
neoadjuvant therapy on overall survival for patients of all stages across the three cohorts. 
As depicted in table 8, age, complete excision, poorly-differentiated grade, vascular and 
perineural invasion, stage, and AR were all shown to be significant independent 
predictors of overall survival. Neoadjuvant CRT was removed from the model, 
suggesting no significant effect on patient survival for this sample when controlled for 
other variables. Of note, complete excision and AR surgery were associated with a 52% 
(0.327 – 0.695; p < 0.001) and 41% (0.468 – 0.748; p < 0.001) risk reduction, 
n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 744	(100) 0.995 0.982	-	1.008 NS
Male	Sex 478	(64) 1.457 1.078	-	1.969 0.014
Adenocarcinoma,	NOS	 622	(84) 0.746 0.514	-	1.082 NS
Neoadjuvant	therapy	 102	(14) 1.214 0.820	-	1.797 NS
Anterior	resection 419	(56) 0.717 0.547	-	0.940 0.016
Tumor	completely	excised 654	(88) 0.608 0.387	-	0.956 0.031
Grade	of	tumor,	poorly	differentiated 78	(10) 1.883 1.284	-	2.761 0.001
Vascular	invasion 137	(18) 2.03 1.505	-	2.739 <	0.001
Lymphatic	invasion 161	(22) 1.986 1.487	-	2.652 <	0.001
Perineural	invasion 100	(13) 2.678 1.951	-	3.675 <	0.001
Stage
I	 190	(26) 1
II 208	(28) 1.856 1.170	-	2.943 0.009
III 269	(36) 3.696 2.441	-	5.595 <	0.001
IV 56	(8) 5.226 2.907	-	9.395 <	0.001
Cohort
NFCCR 192	(26) 1
OFCCR 274	(37) 0.489 0.353	-	0.677 <	0.001
Single	practice 257	(35) 0.778 0.560	-	1.082 NS
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respectively. In contrast, poorly differentiated cancers, vascular invasion, perineural 
invasion, and stage were all associated with poor survival. When controlled for all other 
variables, there was no difference in mortality among the three cohorts for the complete 
sample of patients. 
 
Table 8: Results of multivariate analysis of overall survival for patients with rectal 








 Table 9 shows the results of a multivariate analysis used to assess the impact of 
neoadjuvant CRT on local recurrence for patients among the three cohorts. As depicted in 
the table, the adenocarcinoma cell type and AR surgery were associated with a 46% 
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(0.297 – 0.986; p = 0.045) and a 43% (0.348 – 0.923; p = 0.023) risk reduction, 
respectively. Poor tumor grade was associated with a 2.1 fold increase (1.176 – 3.848; p = 
0.013) in the relative risk of local recurrence compared to less aggressive disease. In 
terms of stage, stage III patients were 2.9 times (1.387 – 6.073; p = 0.005) more likely to 
develop local recurrence. When compared to the NFCCR, the OFCCR was associated 
with a 69% reduced risk of developing local recurrence independent of controlled 
variables.  
 
Table 9: Results of multivariate analysis of local recurrence-free time to event for 





4.4.3 Multivariate model of disease recurrence-free time to event 
Table 10 shows the results of a multivariate analysis used to assess the impact of 
neoadjuvant CRT on disease recurrence for patients among the three cohorts. The results 
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of this analysis suggest neoadjuvant CRT to have no significant association with disease 
recurrence for the total sample of patients. With that said, male patients were 41% (1.009 
– 1.978; p = 0.044) more likely to suffer a disease recurrence in comparison to females. In 
addition, the presence of perineural invasion increased the risk of disease recurrence by 
2.1 fold (1.486 – 3.029; p < 0.001). In regards to staging, progressive disease was more 
likely to result in disease recurrence following surgery. For example, stage III and IV 
patients were 3.27 times (2.054 – 5.214; p < 0.001) and 4.72 times (2.490 – 8.955; p < 
0.001) more likely to develop either a local or distant recurrence. 
 
Table 10: Results of multivariate analysis of disease-free time to event for patients 







4.5 Analysis by stage of disease   
Table 11 shows the 5-year overall survival estimates for patients based on stage of 
the disease. The estimates of 5-year survival between the NFCCR, the OFCCR, and the 
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single practice are similar when stratified by stage. The 5-year survival worsens 
progressively with each advancing stage of disease. With that said, a survival benefit 
seems to be present for earlier-staged disease in the OFCCR cohort, specifically for stage 
II disease (86.5% vs. 67.2% vs. 62.2%; OFCCR vs. NFCCR vs. single practice).  
 







Table 12 shows the 5-year local recurrence-free time to event estimates for 
patients based on stage of disease. As shown in the table, the rate of local recurrence is 
fairly low among each cohort and stage of disease. The NFCCR appears to have a lower 
local recurrence free time to event rate for patients with stage I rectal cancer (86.4% vs 
98.9% vs 96.3%; NFCCR vs. OFCCR vs. single practice). Similarly, the OFCCR appears 
to have a higher rate of local recurrence-free time to event for patients with stage III 






									Stage	1 									Stage	2 				Stage	3 															Stage	4
NFCCR 89 67.2 67.3 17.4
OFCCR 93.8 86.5 64.8 25.3
Single	practice 87.1 62.2 52.3 15.6
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Table 13 shows the 5-year disease-free time to event estimates for patients based 
on stage of disease. As shown in the table, the rate of disease recurrence is fairly low 
among each cohort for earlier stages of disease, specifically stages I and II. The OFCCR 
appears to have a higher disease free time to event rate for patients for all stages of the 
disease in comparison to the NFCCR and OFCCR. In contrast, the NFCCR had lower 
rates of disease-free time to event for stage II disease (63.7% vs 80.6% vs. 76%; NFCCR 
vs. OFCCR vs. Single practice) and stage IV disease (37.3% vs. 54.6% vs. 49.7%; 
NFCCR vs. OFCCR vs. Single practice). 
 
 





									Stage	1 									Stage	2 				Stage	3 															Stage	4
NFCCR 86.4 88.6 78.4 95.5
OFCCR 98.9 90.3 95.3 94.7
Single	practice 96.3 92.4 79.4 92.3
Cohort	 								5-year	Disease-free	time	to	event
(%	without	disease	recurrence	at	follow	up)
									Stage	1 									Stage	2 				Stage	3 															Stage	4
NFCCR 79.9 63.7 50.3 37.3
OFCCR 89.4 80.6 62.2 54.6
Single	practice 82 76xx 50.2 49.7
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4.5.1 Analysis of outcomes for stage I patients  
Table 14 shows the results of overall survival for stage I patients among each 
cohort. There was a larger number of stage I patients in the OFCCR cohort (n = 90) in 
comparison to both the NFCCR (n = 37) and the single practice (n = 67). During the 10-
year period, the NFCCR, OFCCR, and single practice had 6, 25, and 14 deaths, 
respectively. Given that < 50% of the patients of the NFCCR cohort were alive at the 10-
year follow up, a median survival estimate could not be calculated for this cohort. The 
median survival estimates for the OFCCR and single practice cohorts were 115.0 months 
and 167.5 months, respectively. With that said, overall survival between the NFCCR, the 
OFCCR, and the single practice cohorts were not statistically different for stage I patients 
(log rank (mantel-cox) = 2.502; p = 0.286). 
 




Cohort	 N N	 Time	to	event	 Median	time	 95%	CI
of	events (%	alive	at	follow-up) 	to	event	(months)
2	years 4	years 6	years 8	years 10	years
NFCCR 37 6 100 91.7 79.9 79.9 79.9 N/A N/A
OFCCR 90 25 100 95.1 86 70.2 40.1 115.036 (106.181,	123.890)
Single	practice 67 14 91.9 89.9 77 72.2 72.2 167.474 (87.142,	247.806)
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Figure 5 shows the corresponding Kaplan-Meier survival curves for the overall 
survival analysis of stage I patients by cohort. There is significant overlap between the 
curves of each cohort and therefore, there is no statistically significant difference in 





Log rank (Mantel-Cox) = 2.502; df = 2; p = 0.286 
 










Subsequently, a local recurrence-free time to event analysis was performed for 
stage I patients among each cohort. In terms of events, the NFCCR, the OFCCR, and the 
single practice had six, one, and two local recurrences, respectively. Given that neither 
cohort resulted in 50% of the stage I patients having a local recurrence, median time to 
event estimates could not be calculated. At 10-years of follow up, the NFCCR cohort had 
a significantly lower percentage (81.9% vs. 98.9% vs. 96.3%; NFCCR, OFCCR, Single 
practice, respectively) of stage I patients remain without locally recurrent disease (log 
rank (mantel cox) = 12.648; df = 2; p = 0.002).  
 
Table 15: Time to local recurrence-free time to event by cohort for patients with 







Cohort	 N N	 Time	to	event	
of	events (%	with	no	event	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 37 6 89.2 86.4 86.4 81.9 81.9
OFCCR 90 1 98.9 98.9 98.9 98.9 98.9
Single	practice 66 2 96.3 96.3 96.3 96.3 96.3
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Figure 6 shows the corresponding Kaplan-Meier survival curves for the local 
recurrence-free time to event analysis of stage I patients. As shown in the figure, the time 
to event curve of the NFCCR is separated from that of the other cohorts, suggesting a 




Chi = 12.648; df = 2; p = 0.002 
 
Figure 6: Kaplan-Meier curves of local recurrence-free time to event by cohort for 
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Similarly, a disease-free time to event analysis was performed for patients with 
stage I rectal cancer. In terms of events, the NFCCR, the OFCCR, and the single practice 
had 8, 10, and 10 disease recurrences among stage I patients, respectively. Given that 
neither cohort had 50% of its patients suffer a recurrence, median time to event estimates 
could not be provided. At 10 years of follow-up, the NFCCR, the OFFCR, and the single 
practice had 75.5%, 88.1%, and 77.7% of their respective cohorts remain recurrence free. 
With that said, neither cohort was significantly different from the other in terms of 
disease recurrence among stage I patients (log rank (mantel-cox) = 3.532; df = 2; p = 
0.171). 
 




Figure 7 shows the Kaplan-Meier curves corresponding to disease-free time to 
event for patients with stage I disease. The results, stratified by cohort, show a noticeable 
Cohort	 N N	 Time	to	event	
of	events (%	with	no	event	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 35 8 88.6 79.9 79.9 75.5 75.5
OFCCR 90 10 96.6 91.9 88.1 88.1 88.1
Single	practice 65 10 88.9 82 77.7 77.7 77.7
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improvement in the rate of recurrent disease among patients of the OFCCR. However, 
this result did not reach statistical significance. The NFCCR and OFCCR cohorts 




Chi = 3.532; df = 2; p = 0.171 
 
Figure 7: Kaplan-Meier curves of disease-free time to event by cohort for patients 





4.5.2 Analysis of outcomes for stage IV patients  
A survival analysis was performed for advanced staged rectal cancer patients 
separated by cohort. The NFCCR, the OFCCR, and the single practice had 23, 21, and 18 
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stage IV patients, respectively. Of the 23 patients in the NFCCR cohort, 21 had expired 
during the 10-year follow up. During this period, 19 of the 21 patients in the OFCCR 
cohort and 14 of the 18 patients in the single practice cohort had died. Given that more 
than 50% of the sample had passed away, median survival estimates could be calculated 
for each cohort. The median overall survival for the NFCCR, the OFCCR, and the single 
practice cohorts were 16.1 months, 28.2 months, and 21.3 months, respectively. With that 
said, there was no statistically significant difference in survival among the three cohorts 
for stage IV patients (Log rank (Mantel-Cox = 2.911; df = 2; p = 0.233). 
 





Figure 8 shows the Kaplan-Meier curves comparing the overall survival of the 
three cohorts. As depicted in the figure the three lines intersect, suggesting that there is no 
statistically significant difference between the three cohorts in terms of overall survival 
for patients with stage II and III rectal cancer. 
 
 
Cohort	 N N	 Overall	Survival Median	time	 95%	CI
of	events (%	alive	at	follow-up) 	to	event	(months)
2	years 4	years 6	years 8	years 10	years
NFCCR 23 21 43.5 17.4 0 0 0 16.11 (4.943,	27.276)
OFCCR 21 19 60.7 25.3 25.3 12.6 6.3 28.175 (10.351,	46.000)
Single	practice 18 14 39.1 23.4 15.6 7.8 7.8 21.337 (15.218,	27.456)
 





Log rank (Mantel-Cox) = 2.911; df = 2; p = 0.233 
 
Figure 8: Kaplan-Meier curves of overall survival by cohort for patients with stage 





Table 18 shows the results of a disease-free time to event analysis performed for 
stage IV patients compared between each cohort. In terms of the NFCCR, the OFCCR, 
and the single practice, there were 9, 6, and 4 events of recurrent disease within the 10-
year follow up. At the 10-year follow up, the respective proportions of patients without 
recurrent disease for the NFCCR, the OFCCR, and the single practice cohorts were 
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41.4%, 54.6%, and 49.7%, respectively. There was no statistically significant difference 
in terms of time to disease recurrence between each cohort (Log rank (Mantel-Cox) = 
3.356; df = 1; p = 0.187). 
 






Figure 9 shows the Kaplan-Meier curves comparing the disease-free time to event 
of the three cohorts. Given that each line intersects, one can conclude that there is no 
statistically significant difference between the three cohorts in terms of disease-free time 












Cohort	 N N	 Time	to	event	
of	events (%	without	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 18 9 41.4 41.4 41.4 41.4 41.4
OFCCR 21 6 72.8 72.8 54.6 54.6 54.6
Single	practice 17 4 74.6 49.7 49.7 49.7 49.7
 





Chi = 3.356; df = 1; p = 0.187 
 
Figure 9: Kaplan-Meier curves of disease-free time to event by cohort for patients 





4.6 Analysis of patients with stage II and III rectal cancer 
 
4.6.1 Baseline demographics by patient cohort 
Table 19 shows the baseline clinical and pathological differences at baseline 
among the three cohorts for patients with stage II and III disease. This sample comprises 
488 patients with stage II and III disease. Of these, 30.3% (148) of participants come 
 
   
61 
from the NFCCR, 33.4% (163) come from the OFCCR, and another 36.2% (177) come 
from the records of the colorectal surgeon’s single practice. Given that this is a non-
randomized trial, the SPSS 23 computer program was used to investigate potential 
differences at baseline between each of the three cohorts. Pearson chi-square tests were 
performed to investigate patient factors, such as gender, cell type, neoadjuvant therapy, 
surgery type, staging, surgical margins, tumor grade, and presence of invasion. For the 
continuous variable, age, a non-parametric Kruskal-Wallis test was performed to assess 
differences between the three cohorts. 
As depicted in the table, no statistically significant difference exists between each 
cohort in terms of the rate of adenocarcinoma cell type, abdominoperineal resection 
surgery, or poorly differentiated disease. In addition, there was no significant difference 
among the proportion of stage II or III cancers in either cohort. In contrast, significant 
differences existed between the cohorts in terms of clinical characteristics, including age, 
gender, neoadjuvant therapy, and the rate of AR surgery. The median age for the NFCCR, 
the OFCCR, and the single practice was 60 vs. 62 vs. 62 years, respectively (p = 0.021). 
In regards to male gender, the OFCCR had a significantly lower proportion of males in 
comparison to both the NFCCR and the single practice (56% vs. 71% vs. 69%; p = 0.01). 
In addition, there was a significantly increased rate of neoadjuvant CRT in the single 
practice (36%) in comparison to both the NFCCR (5%) and the OFCCR (7%). With 
respects to the type of surgical procedure performed, the rate of AR was significantly 
higher in the single practice cohort than the rates of AR in the NFCCR and OFCCR 
cohorts (69% vs. 55% vs. 51%, respectively; p < 0.001). Patients of the single practice 
had a much lower rate of complete tumor excision than both the NFCCR and the OFCCR 
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(81% vs. 93% vs. 96%, respectively; p < 0.001). In terms of grade, the OFCCR had a 
significantly lower rate of well-differentiated tumors in comparison to the NFCCR and 
the single practice (6% vs. 10% vs. 14%, respectively). In contrast, the single practice had 
a significantly lower proportion of moderately differentiated tumors when compared with 
the NFCCR and the OFCCR (55% vs. 79% vs. 77%; p < 0.001). There were significantly 
different rates of invasion between the three cohorts in terms of vascular invasion (36% 
vs. 14% vs.19%; NFCCR vs. OFCCR vs. Single practice), lymphatic invasion (36% vs. 
17% vs. 29%; NFCCR vs. OFCCR vs. Single practice) and perineural invasion (30% vs. 
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4.6.2 Outcome measurement by patient cohort  
Table 20 shows the results of the survival analysis performed for stage II and III 
patients across cohorts. In the NFCCR cohort, 73 of the 148 stage II and III patients had 
expired within the 10-year follow up. During this period, 66 of the 163 stage II and III 
Total	 NFCCR OFCCR Single	practice P	-	value
n 488 148 163 177
Age;	median	(SD) 62	(10) 60	(9) 62	(10) 62	(12) 0.021
Male	gender;	n	(%) 320	(66) 105	(71) 92	(56) 123(69) 0.01
Cell-type;	n	(%)
Adenoncarcinoma,	NOS;	n	(%) 413	(85) 131(89) 139	(85) 143	(81) NS
Neo-adjuvant	therapy;	n	(%) 83	(17) 8	(5) 12	(7) 63	(36) <	0.001
Type	of	surgery	performed;	n	(%)
Anterior	resection;	n	(%) 288	(59) 82	(55) 83	(51) 123	(69) 0.001
Abdominoperineal	resection;	n	(%) 144	(30) 47	(32) 50	(30) 47	(27) NS
Pathological	staging	(pTNM);	n	(%)
Stage	2;	n	(%) 213	(44) 68	(46) 74	(45) 71	(40) NS
Stage	3;	n	(%) 275	(56) 80	(54) 89	(55) 106	(60) NS
Tumor	entirely	resected;	n	(%) 437	(90) 138	(93) 156	(96) 143	(81) <	0.001
Grade	of	primary	tumor
Well	differentiated;	n	(%) 49	(10) 15	(10) 10	(6) 24	(14) 0.041
Moderately	differentiated	;	n	(%) 340	(70) 117	(79) 125	(77) 98	(55) <	0.001
Poorly	differentiated;	n	(%) 63	(13) 15	(10) 22	(13) 26	(15) NS
Presence	of	invasion;	n	(%)
Vascular	invasion;	n	(%) 110	(23) 53	(36) 23	(14) 34	(19) <	0.001
Lymphatic	invasion;	n	(%) 133	(27) 53	(36) 28	(17) 52	(29) 0.001
Perineural	invasion;	n	(%) 85	(17) 45	(30) 7	(4) 33	(19) <	0.001
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patients in the OFCCR cohort, and 61 of the 177 stage II and III patients in the single 
practice cohort had passed. Median survival estimates for the NFCCR, the OFCCR, and 
the single practice were 90.7 months, 106.0 months, and 82.6 months, respectively. Given 
that each confidence interval overlaps, there was no statistically significant difference in 
survival between cohorts for these patients (Log rank (Mantel-Cox) = 3.532; df = 2; p = 
0.171). 
 





Figure 10 shows Kaplan-Meier curves comparing the results of each cohort. Given 
that each line intersects, one can conclude that there is no statistically significant 
difference between each cohort in terms of overall survival among patients with stage II 
and III disease. 
 
 
Cohort	 N N	 Overall	survival Median	time	 95%	CI
of	events (%	alive	at	follow-up) 	to	event	(months)
2	years 4	years 6	years 8	years 10	years
NFCCR 148 73 91.2 73.6 61.9 49 20.2 90.74 (70.942,	110.537)
OFCCR 163 66 95.7 79.6 68.1 60.5 41.6 105.995 (91.337,	120.652)
Single	practice 177 61 87.7 66.4 51.9 46.5 37.7 82.586 (48.225,	116.947)
 





Chi = 3.532; df = 2; p = 0.171 
 
Figure 10: Kaplan-Meier curves of overall survival by cohort for patients with stage 




A local recurrence-free time to event analysis was performed for patients with 
stage II and III rectal cancer. As shown in table 21, the NFCCR had 26 patients with local 
recurrences, while the OFCCR had 13 patients with local recurrence during the 10-year 
period. The single practice had 20 events of local recurrence during this time. Given that 
the rate of patients without a local recurrence at follow up did not reach < 50%, median 
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time to local recurrence estimates could not be calculated. At 10 years of follow up, the 
proportion of stage II and III patients without local recurrence was 77.6%, 90.1%, and 
83.2%, respectively. The OFCCR had a significantly better prognosis in terms of 
proportion without local recurrence when compared to the other cohorts during the 10-
year follow up (Log rank (Mantel-Cox) = 7.773; df  = 2; p = 0.021).  
 
Table 21: Local recurrence-free time to event by cohort for patients with stage II & 





Figure 11 shows the corresponding Kaplan-Meier curves of local recurrence-time 
to event for patients with stage II and III rectal cancer. As shown in the graph, there is a 
significant separation in the Kaplan-Meier curves, as patients of the OFCCR experienced 
a significantly improved time to local recurrence in comparison to both the NFCCR and 





Cohort	 N N	 Time	to	event	
of	events (%	without	local	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 146 26 93 84.1 83.1 77.6 77.6
OFCCR 163 13 96.2 92.9 92.9 90.1 90.1
Single	practice 176 20 89.7 84.6 82.3 82.3 83.2
 




Log rank (mantel-cox) = 7.773; df = 2; p = 0.021 
 
Fig 11: Kaplan-Meier curves of local recurrence-free time to event by cohort for 





Table 22 shows the results of a disease-free time to event analysis performed for 
patients with stage II and III disease. In terms of event, there were 65 disease recurrences 
in the NFCCR cohort, 49 disease recurrences in the OFCCR cohort, and 49 disease 
recurrences in the single practice cohort. As shown in the table, the OFCCR had a 
significantly improved rate of disease recurrence during the 10-year follow up. Given that 
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the proportion of patients without recurrent disease did not reach 50% in most cohorts, 
median time to event estimates could not be calculated. With that said, stage II and III 
patients of the OFCCR experienced a significantly improved disease-free time to event in 
comparison to patients of the NFCCR and the OFCCR (Log rank (Mantel-Cox = 9.053; 
df = 2; p = 0.011). 
 






Figure 12 shows the time to Kaplan-Meier curves corresponding to disease-free 
time to event for patient with stage II and III disease. As shown in the figure, there is a 
clear separation between the Kaplan-Meier curve corresponding to patients of the 
OFCCR and the curves corresponding to both the NFCCR and the OFCCR. As a result, 
stage II and III patients of the OFCCR had a statistically significant improvement in 
disease-free recurrence in comparison to those of the NFCCR and the single practice. 
Cohort	 N N	 Time	to	event	
of	events (%	without	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
NFCCR 139 65 76.5 60.5 54.5 51.1 44.7
OFCCR 163 49 85.2 71.8 70.5 68.2 68.2
Single	practice 175 49 76.7 61.8 58.2 55.9 55.9
 





Chi = 9.053; df = 2; p = 0.011 
 
Figure 12: Kaplan-Meier curves of disease-free time to event by cohort for patients 





4.7 Analysis of stage II and III patients by neoadjuvant therapy  
 
4.7.1 Overall survival and recurrence outcomes 
 Subsequently, an overall survival analysis was performed to compare patients 
with stage II and III disease based on neoaduvant CRT status. Table 23 shows that of the 
62 patients with locally advanced disease that had neoadjuvant therapy, 15 expired within 
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a 10-year follow up. Of the 415 patients who did not receive neoadjuvant therapy, 148 
had passed away within this period of time. Of patients with stage II and III disease, the 
median overall survival estimates for those receiving neoadjuvant CRT was just 77.8 
months (57.3 – 98.4), whereas the estimate for individuals without neoadjuvant therapy 
was 106 months (90.8 – 121.1). At 10-years of follow up, the proportion of patients still 
alive was 39.0% for those receiving neoadjuvant CRT and 35.1% for patients who did not 
receive this therapy. 
 
Table 23: Overall survival by neoadjuvant therapy status for patients with stage II 





Figure 13 shows the Kaplan-Meier curves corresponding to overall survival for 
patients with stage II and III disease. Given that both curves overlap significantly, there is 
no statistically significant difference in survival between patients with stage II and III 
disease that receive neoadjuvant therapy and those who do not (Log rank (Mantel-Cox) = 
0.012; df = 2; p = 0.913). 
 
Therapy N N	 Overall	survival Median	time	 95%	CI
of	events (%	alive	at	follow-up) 	to	event	(months)
2	years 4	years 6	years 8	years 10	years
Neoadjuvant	CRT 63 16 97.7 87.8 50.5 39 39 77.819 (57.267,	98.371)
None 425 184 90.7 72.5 62.6 53 35.1 105.962 (90.812,	121.112)
 





Chi = 0.012; df = 1; p = 0.913 
 
Fig. 13: Kaplan-Meier curves of overall survival by neoadjuvant therapy status for 





Table 24 shows the results for local recurrence-free time to event for stage II and 
III patients comparing those who received neoadjuvant CRT and those who did not 
receive neoadjuvant therapy. Of the 63 stage II and III patients who received neoadjuvant 
CRT, 5 had a local recurrence within 10 years of follow up. Of the 422 patients who did 
not receive neoadjuvant therapy, 54 had a local recurrence event during the same period. 
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From the table, one can note that the time to event at each point of follow up is fairly 
similar between both groups. At 10 years of follow up, the proportion of patients with 
stage II and III disease without local recurrence was 85.7% and 83.2% for those receiving 
neoadjuvant CRT therapy and those without this therapy, respectively. There was no 
statistically significant difference in overall survival between the two groups (Log rank 
(Mantel-Cox = 0.106; df = 1; p = 0.745)). 
 
Table 24: Local recurrence-free time to event by neoadjuvant therapy status for 






Figure 14 shows the Kaplan-Meier curves corresponding to the local recurrence –
free time to event analysis by neoadjuvant therapy status. As depicted in the graph, both 
curves overlap significantly, suggesting that there is no statistically significant difference 
in overall survival for patients with stage II and III rectal cancer based on neoadjuvant 
therapy. 
 
Therapy N N	 Time	to	event
of	events (%	without	local	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
Neoadjuvant	CRT 63 5 100 85.7 85.7 85.7 85.7
None 422 54 92.4 87.5 86.7 83.2 83.2
 





Log rank (Mantel-Cox) = 0.106; df = 1; p = 0.745 
 
Figure 14: Kaplan-Meier curves of local recurrence-free time to event by 





A disease-free time to event analysis was performed for patients with stage II and 
III disease in order to compare the recurrence rate of patients based on status of 
neoadjuvant therapy. Table 25 shows that 15 of the 62 patients receiving neoadjuvant 
CRT included in the analysis had either a local or distant recurrence. Of the 415 patients 
not receiving neoadjuvant CRT, there were 148 events of disease recurrence. At 10 years 
of follow up, the proportion of individuals without disease recurrence was 55.5% and 
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56.4% for patients receiving neoadjuvant CRT and those receiving treatment without 
neoadjuvant therapy, respectively. There was no statistically significant difference in 
disease-free time to event for patients with stage II and III disease based on neoadjuvant 
therapy (Log rank = 0.074; df = 1; p = 0.786). 
 
Table 25: Disease-free time to event by neoadjuvant therapy status for patients with 





Figure 15 shows the Kaplan-Meier graphs of the disease-free time to event 
analysis comparing outcome by neoadjuvant therapy status. As depicted, there is 
significant overlap between the curves of those receiving neoadjuvant therapy and those 
not receiving neoadjuvant therapy. This suggests that there was no significant difference 
in disease recurrence based on receiving neoadjuvant CRT. 
 
 
Therapy N N	 Time	to	event
of	events (%	without	disease	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
Neoadjuvant	CRT 62 15 90.2 61.7 61.7 55.5 55.5
None 415 148 78.6 65.3 61.7 59.3 56.4
 




Chi = 0.074; df = 1; p = 0.78 
Figure 15: Kaplan-Meier curves of disease-free time to event by neoadjuvant 





4.7.2 Univariate predictors of outcome  
Table 26 shows the results of the univariate analysis of overall survival for 
patients with stage II and III rectal cancer. Age at diagnosis was found to be a significant 
predictor of survival. For every additional year, there was a 3.1% increase in risk of 
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mortality. In addition, the presence of AR surgery was associated with a 46% decreased 
relative risk of mortality (Exp (B) = 0.539; 0.408 – 0.713). In addition, complete excision 
was a significant predictor of overall survival. The results suggest that complete excision 
of the primary tumor can decrease the relative risk of mortality by 50% (Exp (B) = 0.497; 
0.311 – 0.792. Poorly differentiated tumors were associated with a 2 -fold increase in 
relative risk for patients (Exp (B) = 2.009; 1.386 – 2.913). Both vascular invasion (Exp 
(B) = 1.642; 1.212 – 2.226) and perineural invasion (Exp (B) = 1.858; 1.343 – 2.571) 
were associated with poor prognosis in terms of overall survival for patients with locally 
advanced disease. Similarly, stage III patients were 1.4 times more likely to have expired 
than stage II patients during follow-up (Exp (B) = 1.355; 1.017 – 1.806). In terms of 
neoadjuvant chemo-radiation therapy, there was no significant effect on overall survival 
for patients with stage II and III disease. Other patient variables that had no statistically 
significant effect on overall survival included male sex, adenocarcinoma cell type, 
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Table 26: Results of univariate analysis of overall survival for patients with stage II 





 Subsequently, a univariate analysis of local recurrence-free time to event was 
performed. As depicted in table 27, AR surgery was shown to be associated with 44% 
reduction in relative risk of local recurrence (Exp (B) = 0.558; 0.334 – 0.931). Poorly 
differentiated grade of tumors suggested a 2.4 fold increase in the risk of acquiring a local 
recurrence (Exp (B) = 2.397; 1.292 – 4.448). Both vascular invasion (Exp (B) = 2.582; 
1.536 – 4.341) and lymphatic invasion (Exp (B) = 2.072; 1.236 – 3.473) were associated 
with significantly increased risk of developing a local recurrence. Similarly, patients of 
n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 488	(100) 1.031 1.016	-	1.046 <	0.001
Male	Sex 320	(66) 1.301 0.965	-	1.753 NS
Adenocarcinoma,	NOS	 413	(85) 0.836 0.569	-	1.227 NS
Neoadjuvant	CRT 63	(13) 1.029 0.616	-	1.720 NS
Combined	neoadjuvant	therapy	group 83	(17) 1.232 0.834	-	1.820 NS
Anterior	resection 288	(59) 0.539 0.408	-	0.713 <	0.001
Tumor	completely	excised 437	(90) 0.497 0.311	-	0.792 0.003
Grade	of	tumor,	poorly	differentiated 63	(13) 2.009 1.386	-	2.913 <	0.001
Vascular	invasion 110	(23) 1.642 1.212	-	2.226 0.001
Lymphatic	invasion 133	(27) 1.316 0.978	-	1.771 NS
Perineural	invasion 85	(17) 1.858 1.343	-	2.571 <	0.001
Stage
II 213	(44) 1
III 275	(56) 1.355 1.017	-	1.806 0.038
Cohort
NFCCR 148	(30) 1
OFCCR 163	(33) 0.781 0.560	-	1.090 NS
Single	practice 177	(36) 1.075 0.755	-	1.530 NS
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the OFCCR cohort had a 58% reduced risk of developing a local recurrence in 
comparison to patients of the NFCCR (Exp (B) = 0.423; 0.217 – 0.823). The results of the 
local recurrence-free time to event analysis suggest neoadjuvant CRT to have no 
significant effect on time to local recurrence. Other non-significant patient variables in 
the univariate analysis included age at diagnosis, male sex, adenocarcinoma cell type, 
complete excision, perineural invasion, and stage. 
 
Table 27: Results of univariate analysis of local recurrence-free time to event for 





n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 488	(100) 1.011 0.985	-	1.038 NS
Male	Sex 318	(65) 1.133 0.660	-	1.942 NS
Adenocarcinoma,	NOS	 411	(84) 0.592 0.320	-	1.095 NS
Neoadjuvant	CRT 63	(13) 0.859 0.343	-	2.152 NS
Combined	neoadjuvant	therapy	group 83	(17) 0.847 0.384	-	1.866 NS
Anterior	resection 288	(59) 0.558 0.334	-	0.931 0.026
Tumor	completely	excised 435	(89) 0.545 0.246	-	1.203 NS
Grade	of	tumor,	poorly	differentiated 63	(13) 2.397 1.292	-	4.448 0.006
Vascular	invasion 109	(22) 2.582 1.536	-	4.341 <	0.001
Lymphatic	invasion 132	(27) 2.072 1.236	-	3.473 0.006
Perineural	invasion 85	(17) 1.6 0.878	-	2.916 NS
Stage
II 212	(43) 1
III 273(56) 1.537 0.902	-	2.619 NS
Cohort
NFCCR 148	(30) 1
OFCCR 163	(28) 0.423 0.217	-	0.823 0.011
Single	practice 176	(36) 0.977 0.544	-	1.757 NS
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Table 28 shows the results of the univariate analysis of disease-free time to event 
for patients with stage II and III disease. The presence of male sex was shown to be 
associated with a 1.4 fold increase in relative risk of developing either a local or distant 
recurrence. The use of AR surgery suggested a 39% decreased likelihood of having a 
disease recurrence during follow up. Poorly differentiated tumors were associated with a 
1.6 fold increase in developing recurrence. Similarly, presence of invasion was associated 
with an increased risk of disease recurrence, whether it was vascular invasion (Exp (B) = 
1.953; 1.411 – 2.703), lymphatic invasion (Exp (B) = 1.851; 1.350 – 2.539), or perineural 
invasion (2.368; 1.686 – 3.327). In terms of disease staging, stage III patients were 
approximately twice as likely to suffer recurrent disease in comparison to stage II patients 
(Exp (B) = 1.997; 1.434 – 2.781). In comparison to the NFCCR cohort, the OFCCR 
cohort was 42% less likely to have recurrent disease (Exp (B) = 0.579; 0.399 – 0.839). 
The results of the univariate analysis of disease-free time to event suggest that 
neoadjuvant CRT has no significant effect on time to disease recurrence. Other non-
significant patient variables in the univariate analysis included age at diagnosis, 
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Table 28: Results of univariate analysis of disease-free time to event for patients 





4.7.3 Multivariate models of outcomes 
Table 29 shows the results of a multivariate analysis used to assess the impact of 
neoadjuvant CRT on overall survival for patients with stage II and III rectal cancer. 
Neoadjuvant CRT was removed from the model, suggesting no significant effect on 
patient survival for this sample when controlled for other variables. With that said, age at 
diagnosis, AR, complete excision, poorly differentiated grade, perineural invasion, and 
stage were all shown to be significant independent predictors of overall survival. For 
example, both AR and complete excision were shown to decrease the risk of mortality by 
n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 488	(100) 0.996 0.981	-	1.012 NS
Male	Sex 312	(64) 1.425 1.018	-	1.997 0.039
Adenocarcinoma,	NOS	 404	(83) 0.905 0.591	-	1.386 NS
Neoadjuvant	CRT 62	(13) 0.929 0.545	-	1.582 NS
Combined	neoadjuvant	therapy	group 82	(17) 1.11 0.719	-	1.714 NS
Anterior	resection 284	(58) 0.607 0.447	-	0.826 0.001
Tumor	completely	excised 428(88) 0.609 0.368	-	1.010 NS
Grade	of	tumor,	poorly	differentiated 62	(13) 1.571 1.025	-	2.408 0.038
Vascular	invasion 108	(22) 1.953 1.411	-	2.703 <	0.001
Lymphatic	invasion 131	(27) 1.851 1.350	-	2.539 <	0.001
Perineural	invasion 84	(17) 2.368 1.686	-	3.327 <	0.001
Stage
II 208	(43) 1
III 269	(55) 1.997 1.434	-	2.781 <	0.001
Cohort
NFCCR 139	(28) 1
OFCCR 163	(33) 0.579 0.399	-	0.839 0.004
Single	practice 175	(36) 0.898 0.618	-	1.305 NS
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47% (0.402 – 0.706; p < 0.001) and 58% (0.259 – 0.670; p > 0.001), respectively. In 
contrast, poorly differentiated tumors were associated with a 1.8 fold increase (1.207 – 
2.565; p = 0.003) in relative risk of mortality when controlled for other variables in the 
model. In addition, the presence of perineural invasion was associated with 1.7 fold 
increase in relative risk (1.219 – 2.348; p = 0.02) of mortality. Stage III patients were 1.4 
times more likely to have expired when compared to patients with stage II disease (1.030 
– 1.843; p = 0.031). 
 
 
Table 29: Results of multivariate analysis of overall survival for patients with stage 






Table 30 shows the results of the multivariate model of local recurrence-free time 
to event for patients with stage II and III disease. Neoadjuvant CRT was removed from 
the model, suggesting no significant effect on local recurrence for this sample when 
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controlled for other variables. Both the adenocarcinoma cell type and AR surgery were 
shown to decrease the relative risk of local recurrence by 47% (Exp (B) = 0.532; 0.284 – 
0.994) and 50% (Exp (B) = 0.503; 0.298 – 0.847), respectively. In addition, patients of 
the OFCCR were 52% less likely to develop local recurrence (Exp (B) = 0.483; 0.242 – 
0.962). In contrast, the presence of vascular invasion was associated with a 2.4 fold 
increase in relative risk of local recurrence during follow-up (Exp (B) = 2.362; 1.372 – 
4.066).  
 
Table 30: Results of multivariate analysis of local recurrence-free time to event for 





Table 31 shows the results of the multivariate model of disease free time to event 
for patients with stage II and III disease. Neoadjuvant CRT was not included in the final 
model, as it was not a significant predictor of disease-free time to event for this sample 
when controlled for other variables. With that said, AR and complete excision reduced 
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the risk of disease recurrence by 34% (Exp B) = 0.655; 0.480 – 0.894) and 49% (Exp (B) 
= 0.514; 0.309 – 0.856), respectively. In contrast, male sex, vascular invasion, perineural 
invasion, and stage were all independent significant predictors of poor disease recurrence 
prognosis. Specifically, male patients were 1.4 times (Exp (B) = 1.436; 1.024 – 2.013) 
more likely to have a recurrence in comparison to their female counterparts. Similarly, the 
presence of vascular invasion was associated with a 1.4 fold (Exp (B) = 1.003 – 2.054) 
increase in relative risk of developing recurrent disease, whereas perineural invasion was 
associated with a 1.9 fold (Exp (B) = 1.864; 1.280 – 2.716) increase in risk. Patients with 
stage III disease were 1.9 times (Exp (B) = 1.920; 1.373 – 2.686) more likely to develop 
recurrence than those with stage II disease. 
 
Table 31: Results of multivariate analysis of disease-free time to event for patients 
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4.8 Analysis of patients with stage II and III disease following December 2003 
 
4.8.1 Baseline demographics  
Table 32 shows the predictors of neoadjuvant CRT for patients with stage II and 
III rectal cancer diagnosed after December 2003. Of the 118 patients with locally 
advanced disease diagnosed after 2003, 38.9% received neoadjuvant CRT while 61% of 
patients did not receive this therapy despite a universal shift in clinical practice. As 
depicted in the table, no significant difference exists between patients receiving 
neoadjuvant CRT and those without neoadjuvant therapy in terms of age, adenocarcinoma 
cell type, type of surgery performed, stage, tumor grade, vascular invasion, and perineural 
invasion. In contrast, the patients who received neoadjuvant CRT differed from those not 
receiving this therapy in terms of the proportion of males, complete resection, and 
lymphatic invasion. Specifically, 85% of the sample receiving neoadjuvant CRT were 
males, whereas only 64% of those without neoadjuvant CRT were males (p = 0.014). The 
proportion of patients with complete tumor resection for those receiving neoadjuvant 
CRT and those without neoadjuvant CRT was 54% and 89%, respectively (p < 0.001). Of 
the 46 patients in the neoadjuvant CRT group, 9% had lymphatic invasion, whereas 29% 
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Table 32: Predictors of neoadjuvant chemo-radiation therapy for patients with stage 







4.8.2 Overall survival and recurrence outcomes 
Table 33 shows the results of the overall survival analysis for patients with stage 
II and III rectal cancer diagnosed following December 2003. Of the 46 patients who 
received neoadjuvant CRT, 7 had expired within the 10-year follow up.  Of the 72 
patients with stage II and III disease who did not receive neoadjuvant therapy, 25 of those 
individuals had died within the same period. Median survival estimates were calculated, 
as the percentage of patients alive at follow-up reached less than 50% in both groups. The 
Total	 Preoperative	chemoradiation 	No	preoperative	therapy P	-	value
n 118 46 72
Age;	median	(SD) 62	(11) 61	(10) 63	(12) NS
Male	gender;	n	(%) 85	(72) 39	(85) 46	(64) 0.014
Adenocarcinoma,	NOS;	n	(%) 94	(80) 35	(76) 59	(82) NS
Type	of	surgery	performed;	n	(%)
Anterior	resection;	n	(%) 84	(71) 30	(65) 54	(75) NS
Abdominoperineal	resection;	n	(%) 34	(29) 16	(35) 16	(22) NS
	Stage;	n	(%)
Stage	2;	n	(%) 49	(42) 18	(39) 31	(43) NS
Stage	3;	n	(%) 69	(58) 28	(61) 41	(57) NS
Tumor	entirely	resected;	n	(%) 89	(75) 25	(54) 64	(89) <	0.001
Grade	of	primary	tumor
Well	differentiated;	n	(%) 11	(9) 3	(7) 8	(11) NS
Moderately	differentiated	;	n	(%) 63	(53) 17	(37) 46	(64) NS
Poorly	differentiated;	n	(%) 16	(14) 4	(9) 12	(17) NS
Presence	of	invasion;	n	(%)
Vascular	invasion;	n	(%) 17	(14) 4	(9) 13	(18) NS
Lymphatic	invasion;	n	(%) 25	(21) 4	(9) 21	(29) 0.012
Perineural	invasion;	n	(%) 20	(17) 9	(20) 11	(15) NS
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median survival estimate for patients receiving neoadjuvant CRT was 62.8 months (51.6 
– 74.0), whereas the median survival for patients who did not receive neoadjuvant therapy 
was 47.2 months (38.0 – 56.5). Patients in the neoadjuvant CRT group experienced a 
significantly improved overall survival rate in comparison to those receiving treatment 
without neoadjuvant therapy (Log rank (Mantel-Cox) = 3.889; df = 1; p = 0.049). 
 







 Figure 16 shows the Kaplan-Meier curves corresponding to the overall survival 
analysis performed for patients with stage II and III disease diagnosed after December 
2003. As shown in the graph, two patient survival curves are present based on status of 
receiving neoadjuvant CRT. There is clear separation between the overall survival curves, 
suggesting that there is a statistically significant difference in overall survival between the 
two groups. 
 
Therapy N N	 Overall	survival Median	survival 95%	CI
of	events (%	alive	at	follow-up) 	(months)
2	years 4	years 6	years 8	years 10	years
Neoadjuvant	CRT 46 7 96.3 88.9 29.6 0 0 62.795 (51.570,	74.019)
None 72 25 83.6 49.7 26.9 26.9 26.9 47.244 (38.025,	56.463)
 





Chi = 3.889; df = 1; p = 0.049 
 
Figure 16: Kaplan-Meier curves of overall survival for patients with stage II & III 





Table 34 shows the results of the local recurrence-free time to event for patients 
with stage II and III rectal cancer. Of the 46 patients receiving neoadjuvant CRT, just 3 
individuals suffered locally recurrent disease during the 10-year follow up. Of the 72 
patients without neoadjuvant therapy, 8 individuals had a local recurrence event during 
this time. Given that the percentage of patients without local recurrence in either group 
 
   
88 
did not drop below 50%, median time to event estimates could not be calculated. At 10 
years of follow-up, 83.2% of the patients receiving neoadjuvant CRT were without local 
recurrence. In comparison, just 65.2% of the patients who did not receive neoadjuvant 
therapy were without local recurrence. With that said, there was no statistically significant 
difference between the two groups in terms of local recurrence-free time to event (Log 
rank (Mantel-Cox) = 0.508; df = 1; p = 0.476)). 
 
Table 34: Local recurrence-free time to event for patients with stage II and III rectal 







Figure 17 shows the Kaplan-Meier curves corresponding to the local recurrence-
free time to event analysis for patients with locally advanced disease diagnosed after 
December 2003. As shown in the graph, the results have been separated into two curves 
in order to determine if a difference exists, regarding time to local recurrence for patients 
receiving neoadjuvant CRT and those treated without neoadjuvant CRT. Both of the 
Therapy N N	 Overall	time	to	event
of	events (%	without	local	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
Neoadjuvant	CRT 46 3 100 83.2 83.2 83.2 83.2
None 72 8 86.9 86.9 65.2 65.2 65.2
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Kaplan-Meier curves intersect, suggesting no statistically significant difference between 





Chi = 0.508; df = 1; p = 0.476 
 
Figure 17: Kaplan-Meier curves of local recurrence-free time to event for patients 





Table 35 shows the results of disease-free time to event of patients with stage II 
and III rectal cancer diagnosed following December 2003. Of the 45 patients receiving 
neoadjuvant CRT, 8 individuals had either a local or distant recurrence during the 10-year 
follow up. Of the 72 patients who received treatment without neoadjuvant CRT, 16 
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patients suffered recurrent disease within this period. Given that the percentage of 
patients without recurrence in either group did not reach 50%, median time to event 
estimates could not be calculated. At 10 years of follow up, there were no patients 
without recurrent disease in the group that received neoadjuvant CRT, whereas 47.8% of 
the patients who did not receive neoadjuvant therapy were without recurrence. Still, no 
statistically significant difference in disease-free time to event was observed between the 
two groups (Log rank (Mantel-Cox = 0.143; df = 1; p = 0.705)). 
 
Table 35: Time to disease-free time to event for patients with stage II and III rectal 






Figure 18 shows the Kaplan-Meier curves corresponding to disease-free time to 
event for stage II and III patients diagnosed following December 2003. The results are 
stratified based on neoadjuvant CRT status, creating two separate curves. Both curves 
intersect, suggesting that there is no significant difference between patients receiving 
neoadjuvant CRT and those receiving treatment without neoadjuvant therapy. 
Therapy N N	 Overall	time	to	event
of	events (%	withough	recurrence	at	follow-up)
2	years 4	years 6	years 8	years 10	years
Neoadjuvant	CRT 45 8 88 71 71 0 0
None 72 16 74.6 71.8 47.8 47.8 47.8
 





Log-rank (Mantel-Cox) = 0.143; df = 1; p = 0.705 
 
Figure 18: Kaplan-Meier curves of disease-free time to event for patients with stage 





4.8.4 Univariate predictors of outcome 
Subsequently, a univariate analysis of overall survival was performed for patients 
with stage II and III rectal cancer. As depicted in table 36, age at diagnosis was shown to 
be associated with overall survival. For every additional year of age, the relative risk of 
mortality increased by 5.6% (1.022 – 1.092; p = 0.001). Similarly, poorly differentiated 
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tumor grade was associated with 2.9 fold increase (1.233 – 6.933; p = 0.015) in the 
relative risk of mortality. In addition, vascular invasion was shown to be associated with 
2.3 fold increase in relative risk for this sample (1.030 – 5.177; p = 0.042). In contrast, 
male sex, adenocarcinoma cell type, AR, complete excision, poorly differentiated grade, 
stage, lymphatic invasion, and perineural invasion had no significant effect on overall 
survival for this sample. Neoadjuvant CRT was shown to have no statistically significant 
effect on overall survival for patients with stage II and III rectal cancer diagnosed 





Table 36: Results of univariate analysis of overall survival for patients with stage II 





n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 118	(100) 1.056 1.022	-	1.092 0.001
Male	sex 85	(72) 0.47 0.230	-	0.959 NS
Adenocarcinoma,	NOS	 94	(80) 0.967 0.414	-	2.259 NS
Neoadjuvant	chemoradiation	therapy 46	(39) 0.438 0.188	-	1.018 NS
Anterior	resection 84	(71) 0.867 0.407	-	1.844 NS
Tumor	completely	excised 89	(75) 2.435 0.845	-	7.014 NS
Grade	of	tumor,	poorly	differentiated 16	(14) 2.937 1.233	-	6.993 0.015
Vascular	invasion 17	(14) 2.309 1.030	-	5.177 0.042
Lymphatic	invasion 25	(21) 1.716 0.833	-	3.534 NS
Perineural	invasion 20	(17) 2.169 0.992	-	4.742 NS
Stage
II 49	(42) 1
III 69	(58) 1.432 0.673	-	3.047 NS
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Table 37 shows the results of the univariate analysis of local recurrence-free time 
to event for patients with stage II and III rectal cancer diagnosed after December 2003. As 
depicted in the table, no association was found between any patient variables included in 
this analysis and one’s risk of developing local recurrence. Of note, neoadjuvant CRT had 
no significant effect on local recurrence-free time to event for this cohort of patients. 
 
 
Table 37: Results of univariate analysis of local recurrence-free time to event for 





Table 38 shows the results of the univariate analysis of disease-free time to event 
for patients with stage II and III rectal cancer diagnosed post-December 2003. As 
depicted in the table, the presence of vascular invasion was associated with a 4.8 fold 
n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 118	(100) 1.043 0.989	-	1.100 NS
Male	sex 85	(72) 1.062 0.280	-	4.029 NS
Adenocarcinoma,	NOS	 94	(80) 0.811 0.215	-	3.062 NS
Neoadjuvant	chemoradiation	therapy 46	(39) 0.62 0.164	-	2.340 NS
Anterior	resection 84	(71) 0.712 0.208	-	2.436 NS
Tumor	completely	excised 89	(75) 3.524 0.447	-	27.796 NS
Grade	of	tumor,	poorly	differentiated 16	(14) 2.484 0.512	-	12.044 NS
Vascular	invasion 17	(14) 1.641 0.354	-	7.609 NS
Lymphatic	invasion 25	(21) 0.75 0.162	-	3.478 NS
Perineural	invasion 20	(17) 1.618 0.428	-	6.118 NS
Stage
II 49	(42) 1
III 69	(58) 3.329 0.719	-	15.410 NS
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(2.043 – 11.384; p < 0.001) increase in relative risk of developing recurrent disease. 
Similarly, patients with lymphatic invasion were suggested to be three times more likely 
(1.308 – 6.688; p = 0.009) to suffer recurrent disease. Perineural invasion was associated 
with a 4.1 fold increase (1.805 – 9.226; p = 0.001) in the relative risk of disease 
recurrence. Patients with stage III disease were 9.3 times more likely (2.169 – 40.294; p = 
0.003) to suffer recurrence in comparison to patients with stage II disease. In contrast, age 
at diagnosis, male sex, adenocarcinoma cell type, neoadjuvant CRT, AR, complete 
resection, and tumor grade had no statistically significant association with disease 
recurrence among this cohort of patients. Of note, no association was found between 
neoadjuvant CRT and disease-free time to event. 
 
Table 38: Results of univariate analysis of disease-free time to event for patients 




n;	(%) Exp	(B) 95%	Confidence	interval P-value
Age	at	diagnosis	(per	year) 118	(100) 1.001 0.964	-	1.039 NS
Male	sex 84	(71) 0.974 0.400	-	2.370 NS
Adenocarcinoma,	NOS	 94	(80) 0.726 0.286	-	1.842 NS
Neoadjuvant	chemoradiation	therapy 45	(38) 0.848 0.362	-	1.988 NS
Anterior	resection 84	(71) 1.04 0.409	-	2.641 NS
Tumor	completely	excised 89	(75) 1.118 0.415	-	3.014 NS
Grade	of	tumor,	poorly	differentiated 16	(14) 1.919 0.639	-	5.763 NS
Vascular	invasion 17	(14) 4.822 2.043	-	11.384 <	0.001
Lymphatic	invasion 25	(21) 2.958 1.308	-	6.688 0.009
Perineural	invasion 20	(17) 4.08 1.805	-	9.226 0.001
Stage
II 48	(41) 1
III 69	(58) 9.348 2.169	-	40.294 0.003
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4.8.4 Multivariate predictors of outcome  
A multivariate analysis of overall survival was performed for patients with stage II 
and III rectal cancer diagnosed after December 2003 (see table 39). When controlling for 
all other variables included in the analysis, neoadjuvant CRT was not significantly 
associated with overall survival. With that said, the magnitude of benefit was a 58.2% 
reduction in relative risk of mortality. 
 
Table 39: Preliminary results of multivariate analysis of overall survival for patients 
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Table 40 shows the final results of the multivariate model used to describe overall 
survival for patients with locally advanced disease diagnosed post-December 2003. 
Following the removal of non-statistically significant variables in the model, only age at 
diagnosis, male sex, vascular invasion, and stage were independent predictors of overall 
survival. Specifically, each additional year of age was associated with a 6.8% increase 
(1.032 – 1.105; < 0.001) in the relative risk of mortality. Male patients had a 64% reduced 
risk (0.165 – 0.778; p = 0.009) of mortality in comparison to their female counterparts. In 
addition, the presence of vascular invasion was associated with a 3.3 fold increase (1.410 
– 7.766; p = 0.006) in the relative risk of mortality. In terms of stage of disease, stage III 
patients were 2.9 times more likely (1.210 – 6.780; p = 0.017) to expire during the 10-
year follow up in comparison to patients with stage II disease. 
 
Table 40: Final model of multivariate analysis of overall survival for patients with 





Given that no variables were associated with local recurrence-free time to event in 
the previous univariate analysis of patients with locally advanced disease following 
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December 2003, one would expect that no multivariate regression model would be able to 
describe a relationship with local recurrence-free time to event for this cohort of patients. 
A multivariate analysis was performed and there were no statistically significant 
predictors of local recurrence-free time to event for patients with stage II and III rectal 
cancer diagnosed post-December 2003. 
Table 41 shows the results of the multivariate analysis performed for patients with 
stage II and III disease diagnosed post-December 2003. As depicted in the table, only 
vascular invasion and stage of disease were found to be associated with disease 
recurrence for this cohort of patients. Specifically, the presence of vascular invasion was 
associated with a 4.1 fold increase (1.751 – 9.721; p = 0.001) in the relative risk of 
developing either a local or distant recurrence. Similarly, stage III patients were 9.3 times 
more likely to suffer recurrent disease in comparison to patients with stage II disease. Of 
note, neoadjuvant CRT was not found to be associated with disease-free time to event for 
patients of this cohort. 
 
Table 41: Results of multivariate analysis of disease-free time to event for patients 
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Chapter 5: DISCUSSION 
 
 Most evidence from the current literature suggests that neoadjuvant CRT 
improves the local recurrence-free time to event for patients with stage II and III rectal 
cancer, while offering no significant improvement in patient survival. Still, there is an 
ongoing need to evaluate the effect of neoadjuvant CRT on patient prognosis. Our 
objective was to determine if neoadjuvant CRT independently predicts improved patient 
survival for patients with stage II & III rectal cancer. By evaluating the change in clinical 
practice from post-operative to neoadjuvant CRT in three separate cohorts of patients, this 
study provides an interpretation of the prognostic factors that predict disease recurrence 
and overall survival of patients with locally advanced rectal cancer. 
 
 
5.1 Predictors of survival and recurrence by patient cohort  
Firstly, the prognostic variables pertinent to rectal cancer were examined between 
the three patient cohorts. The results of the analysis shown in Table 1 suggest that the 
cohorts differ at baseline significantly, especially with respects to the patients of the 
NFCCR and the single practice cohorts. Given that a portion of the single practice sample 
was accrued following 2004, these individuals were much more likely than those of the 
NFCCR to have received neoadjuvant CRT (27% vs. 6%; p < 0.001). Other studies show 
a similar change in clinical practice supporting neoadjuvant therapy following the 
publishing of the Sauer et al. paper in 2004. For example, a 2014 trial by Wiegering et.al 
examined treatment outcomes in rectal cancer between two decades. Their results 
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suggested that the usage of neoadjuvant CRT had increased from 5.3% throughout 1993-
2001 to 35.3% during 2002 -2010 (p < 0.001). Similarly, Law et al. examined treatment 
outcomes in rectal cancer between two decades using the periods 1993-2001 and 2002-
2011. With respects to all stages of the disease, the rates of neoadjuvant radiation without 
chemotherapy had increased from 4.4% during 1993-2001 to 17.4% throughout 2002 – 
2011 (p < 0.001).  
In addition, the single practice had a higher rate of AR surgery in comparison to 
both that of the NFCCR and the OFCCR (68% vs. 54% vs. 47%, respectively; p < 0.001). 
AR surgery is often performed for tumors located within the proximal one-third of the 
rectum and this level of tumor tends to have a better prognosis in terms of lower 
recurrence and mortality rates. With that said, the surgeon of the single practice 
completed fellowship training in colorectal surgery. The higher rate of AR in the single 
practice of this study reflects the surgeon’s experience and comfort performing low lying 
ARs for tumors past the proximal one-third of the rectum, thus avoiding permanent 
colostomy for patients with more challenging procedures. In addition, the single practice 
had a higher rate of well-differentiated cancers than both the NFCCR and the OFCCR 
(16% vs 10% vs 10%, respectively; p = 0.01). The main surgeries performed in this study 
comprise AR and APR. With that said, a subset of patients received a local excision, 
which is associated with a higher rate of incomplete margins and worse prognosis. Of 
note, there were 0, 18, and 3 local excisions in the NFCCR, OFCCR, and single practice, 
respectively. These cases were included in the analysis and we acknowledge this as a 
limitation to our study design.  
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In addition, there was a baseline difference between the numbers of rectal 
adenocarcinomas between the three cohorts, with the patients of the single practice 
having a significantly lower rate of adenocarcinomas (81% vs. 89% vs. 87%, single 
practice vs. NFCCR & OFCCR, respectively). As mentioned, the other options of cell 
type included in this study were tumors of either mucinous or signet ring cell origin. Each 
of these cell types are associated with a significantly worse prognosis than non-specified 
adenocarcinoma and as a result, our study group decided to focus solely on the non-
specified adenocarcinoma cell type vs. subtype adenocarcinoma. An analysis of the 
mucinous cell type was performed, suggesting no statistically significant difference in the 
proportion of this poor prognostic indicator between cohorts (10.6% vs. 8.7% vs. 14.7%; 
p = NS).  
The single practice actually had a lower proportion of complete tumor excision in 
comparison to both the NFCCR and the OFCCR (85% vs. 90% vs. 93%, respectively; p = 
0.002). There are many predictors that could potentially account for this result, including 
tumor stage (T4 vs. T2-T3 tumor), neoadjuvant CRT, poor differentiation, Type of 
surgery (AR vs. APR), cohort, previous local excision, and mucinous cell type. A 
multivariate model of complete excision was proposed for this project, but ultimately our 
group decided against performing this analysis given that the number of cases with 
incomplete excision was so small. With a larger sample of patients, we suspect that the 
discrepancy of incomplete excision between cohorts would become statistically non-
significant. Lastly, the NFCCR had a statistically higher proportion of vascular, 
lymphatic, and perineural invasion. 
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 In terms of overall survival, no statistically significant difference was found 
between the three cohorts. With that said, the OFCCR experienced improvements in both 
disease-free time to event and local recurrence-free time to event. This could partly be 
explained by the methodology employed by OFCCR, as this cohort did not enroll proxy 
consent when ascertaining their sample. As a result, the patients of the OFCCR likely 
include a larger proportion of individuals who had favorable prognostic factors in 
comparison to other cohorts.  
In terms of univariate predictors of survival for all patients included in the study, 
table 5 shows that age, male sex, AR, complete excision, poorly differentiated grade, 
vascular invasion, lymphatic invasion, perineural invasion, stage, and the OFCCR cohort 
were all significant predictors of mortality. This is interesting given the favorable 
prognostic baseline of the OFCCR cohort. When controlling for all other factors included 
in the analysis, the OFCCR cohort, as well as male sex and lymphatic invasion were no 
longer significantly associated with worsened survival. Neoadjuvant CRT had no 
significant effect on overall survival for patients in both the univariate and multivariate 
models during this phase of the experiment. With that said, this portion of our analysis 
comprised the total sample of patients with disease of all stages, whereas neoadjuvant 
CRT is a therapy specific to stage II and III rectal cancer. In contrast, the 2016 paper by 
Law et al. also performed a multivariate analysis including patients with all stages of 
rectal cancer. Their multivariate analysis showed neoadjuvant radiation without 
chemotherapy to improve overall survival (exp (B) =0.688; p = 0.011) for patients of all 
stages when controlling for all other variables in their model.  
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With regards to locally recurrent disease for all stages, table 6 summarizes the 
univariate predictors of local recurrence, including adenocarcinoma cell type, complete 
tumor excision, poorly differentiated grade, vascular invasion, lymphatic invasion, 
perineural invasion, stage, and the OFCCR cohort. When controlled for all factors 
included in the analysis, the presence of vascular, lymphatic and perineural invasion was 
no longer significantly associated with locally recurrent disease. Again, neoadjuvant CRT 
was not a significant independent predictor of local recurrence in both univariate and 
multivariate analyses for patients of all stages. Interestingly, the OFCCR cohort was a 
significant independent predictor of local recurrence-free time to event, but not overall 
survival or disease-free time to event. The improved prognosis of this cohort can be partly 
explained by the absence of proxy consent. The multivariate analysis suggests patients of 
the OFCCR to have a 69% reduction in relative risk of developing locally recurrent 
disease, yet this had a limited effect on the overall survival of this cohort when 
considering all stages. 
In terms of disease-free time to event, the univariate analysis describes the 
predictors of recurrence for all stages of disease across three different cohorts of patients. 
Male sex, AR, complete resection, poorly differentiated grade, vascular invasion, 
lymphatic invasion, perineural invasion, stage, and the OFCCR cohort were all significant 
predictors of disease recurrence. However, when each variable was tested in the 
multivariate model, only male sex, stage, and perineural invasion remained as significant 
independent predictors of disease recurrence. Again, neoadjuvant CRT had no significant 
effect on disease-free time to event for this sample. Although the current body of 
evidence suggests neoadjuvant CRT to improve the rates of both distant and local 
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recurrence, this was not shown for patients of all stages in this phase of our analysis. 
Furthermore no mortality benefit was demonstrated when considering this broad sample. 
 
 
5.2 Predictors of survival and recurrence by stage of disease 
A sub-group analysis for patients with stage I rectal cancer was performed, 
comparing the rates of overall survival between the three cohorts. As expected, table 14 
shows a relatively low mortality rate for these patients with early staged disease. Median 
survival estimates could be calculated for only the OFCCR and single practice, which 
were 115.0 and 167.5 months, respectively. The overall survival at 10 years for patients 
with stage I disease in the NFCCR, OFCCR, and single practice was 79.9%, 40.1%, 
72.2%, respectively. The Memorial Sloan Kettering cancer group reported a 10-year 
disease free time to event rate of 83% for patients with T1 rectal cancer, which is similar 
to our results for early-staged rectal cancers. The 2016 Law et al. paper found that at 5 
years of follow up, the cancer-specific survival for stage I patients was 92.0% from 1993 
- 2001 and 92.9% from 2002 – 2011. These estimates are similar to the results of our 
study, as the 4-year overall survival rate for the NFCCR, OFCCR, and single practice 
were 91.7%, 95.1%, and 89.9%. Although these estimates are neither cancer-specific nor 
measure the same time of follow up as the study by Law et al, the estimates between 
studies loosely reflect each other. Our study found no significant difference in the overall 
survival for patients diagnosed with stage I rectal cancer between cohorts.  
In addition, the rate of local recurrence for stage I disease was compared across 
cohorts. The proportion of patients alive without local recurrence at 10 years of follow-up 
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was 81.9%, 98.9%, and 96.3%, respectively. Although median survival estimates could 
not be calculated, patients of the NFCCR experienced a significantly higher rate of local 
recurrence (Chi = 12.648; p value = 0.002). The NFCCR had 6 events of local recurrence 
compared to 1 event and 2 events in the OFCCR and single practice, respectively. This 
may be due to the fact that stage I rectal cancers are usually managed by local excision 
with good recurrence outcome. Alternatively, error could have occurred in data collection 
given the retrospective design of our study. With respects to the study by Law et al., local 
recurrence free time to event for patients with stage I disease at 5 years of follow up was 
92.6% from 1993-2001 and 96.6% from 2002-2011, which reflects the results of our 
study at 4 years of follow up (86.4%, 98.9%, and 96.3%; NFCCR, OFCCR, single 
practice, respectively). Similarly, a study by Kajiwara in 2010, which examined the local 
recurrence rates of stage I rectal cancers, demonstrated a rate of 5 – 26% in cases treated 
with local excision and adjuvant therapy (Kajiwara et al.; 2010). 
The rate of disease-free time to event for patients with stage I disease for our 
study was calculated for each cohort. At 10 years of follow up, the percentage of stage I 
patients without recurrence were 75.5%, 88.1%, and 77.7% for the NFCCR, the OFCCR, 
and single practice, respectively. The Memorial Sloan Kettering cancer group reported a 
10-year recurrence rate of 83% for patients with T1 rectal cancer, which is similar to our 
results for early-staged rectal cancers (Paty, 2002). 
Subsequently, a subgroup analysis was then performed for patients with stage IV 
rectal cancer. Table 17 compares the respective overall survival rates for patients of each 
cohort. Due to the progressive nature of rectal cancer, the survival for patients with stage 
IV disease would be expected to be the poorest in comparison to earlier-staged rectal 
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cancer. The median overall survival estimates for patients with stage IV rectal cancer in 
our analysis were 16.11 months, 28.175 months, and 21.337 months for the NFCCR, the 
OFCCR, and the single practice, respectively. There was no statistically significant 
difference in the time to death between each cohort for patients with stage IV cancer. The 
2016 paper by Law et al. demonstrates a median survival of 14.2 months from 1993 – 
2001 and 20.4 months from 2002 – 2011, indicating a statistically significant 
improvement among stage IV patients in the latter decade (Law, 2016). At four years of 
follow up, the percentage of stage IV patients who were still alive was 17.4%, 25.3%, and 
23.4% for the NFCCR, the OFCCR, and the single practice, respectively. The 2014 study 
by Wiegering et al. reported a 5-year survival rate of nearly 30% (Wiegering, 2014). With 
respects to disease free time to event for stage IV rectal cancers, median time to event 
estimates could not be calculated. However, the percentage of patients without an event at 
6 years of follow-up was 41.4%, 54.6%, and 49.7% for the NFCCR, OFCCR, and single 
practice cohorts, respectively. There is limited data in the literature that has calculated 
disease-free time to event for stage IV patients, likely due to the poor survival and 
subsequent low rate of further metastasis in this group. 
 
 
5.3 Predictors of survival and recurrence of patients with stage II & III rectal cancer 
by cohort 
Subsequently, a sub-group analysis was performed for patients with stage II and 
III rectal cancer, as our primary objective is to evaluate neoadjuvant CRT for patients 
with locally advanced disease. The baseline clinical and pathological characteristics of 
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each cohort were similar to table 1 after removing patients with stages I and IV of the 
disease. Still, the greatest differences were noted between the NFCCR and single practice 
cohorts. Given that the majority of patients from the single practice were recruited 
following December 2003, this cohort had a higher rate of patients treated with 
neoadjuvant CRT (36% vs. 5% vs. 7%; p > 0.001). With the exception of complete 
resection, the single practice cohort had more favorable prognostic indicators for patients 
with stage II and III rectal cancer. For example, the single practice cohort had an 
increased rate of AR in comparison to both the NFCCR and the OFCCR cohorts (69% vs. 
55% vs. 51%; p = 0.001). In addition, the single practice had a significantly lower 
proportion of moderately differentiated tumors in comparison to the NFCCR and the 
OFCCR (55% vs. 79% vs. 77%; p > 0.001). In comparison to the single practice cohort, 
the NFCCR had much higher rates of vascular invasion (36% vs. 19%), lymphatic 
invasion (36% vs. 29%), and perineural invasion (30% vs. 19%). In contrast, the single 
practice was significantly worse than other cohorts in terms of obtaining complete 
margins, which has been shown to be one of the most significant predictive factors of 
recurrent disease. Ultimately, none of these prognostic differences translated to any 
significant difference in overall survival between the three patient cohorts for stage II and 
III disease. Patients of the OFCCR cohort experienced significantly improved disease-
free and local recurrence-free time to event. However, this may be attributed to the 
absence of proxy consent when collecting this sample of patients. When analyzed in 
terms of neoadjuvant CRT status, no differences existed among the three main outcomes 
between patients receiving neoadjuvant CRT and those managed without this therapy. 
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The univariate analysis shown that AR surgeries were beneficial for patients with 
stage II and III disease in terms of overall survival, locally recurrence-free time to event 
and disease-free time to event. Complete excisions had no effect on the rate of recurrent 
disease, whether local or distant metastasis, however, it was associated with a survival 
benefit. Poorly differentiated disease was associated with poor prognosis regarding all 
three outcomes examined. As expected, vascular invasion was shown to worsen local 
recurrence, distant recurrence, and overall survival. Lymphatic invasion was a poor 
prognostic factor for local recurrence-free time to event and disease-free time to event, 
but this did not worsen patient survival. Perineural invasion was associated with both 
recurrent disease and mortality. Although, stage III patients were associated with 
recurrent disease, there was no association with local recurrence specifically. As 
expected, stage III patients had a greater relative risk for mortality. Although, patients of 
the OFCCR had improved disease-free, and local recurrence-free time to event, this did 
not translate to a survival benefit for stage II and III patients. 
When controlled for all other factors in the analysis, age, AR, complete excision, 
poorly differentiated grade, perineural invasion, and stage were all significant 
independent predictors of overall survival. Each of these prognostic factors had the 
expected individual effect on overall survival that is documented in the literature. 
Interestingly, vascular invasion no longer had an effect on overall survival when 
controlling for other variables in the analysis and this result differs from the current body 
of literature. In terms of a multivariate model for local recurrence-free time to event, 
adenocarcinoma cell type, AR, vascular invasion, and the OFCCR cohort were all 
significant independent predictors of event. When controlling for all prognostic factors 
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included in the analysis, poorly differentiated grade and lymphatic invasion were no 
longer significantly associated with local recurrence.  
For the multivariate model of disease-free time to event, male sex, AR, complete 
excision, vascular invasion, perineural invasion, and stage were all significant 
independent predictors of event. Interestingly, poorly differentiated grade, lymphatic 
invasion, and the OFCCR cohort were no longer significant predictors of disease 
recurrence after controlling for all variables in the analysis. With that said, patients of the 
OFCCR cohort may have been less likely to have a local recurrence, but this result did 




5.4 Predictors of survival and recurrence of patients with stage II and III rectal 
cancer by neoadjuvant therapy 
The main portion of the analysis focused on patients with stage II and III rectal 
cancer who were diagnosed following December 2003, which approximates the time 
period that neoadjuvant CRT was incorporated in clinical practice. Of the total 63 stage II 
and III patients of the single practice who were treated with neoadjuvant CRT, 46 were 
diagnosed post December-2004. In comparison, the 2004 seminal paper by Sauer et al. 
had 62 patients who received neoadjuvant CRT. From table 32, it is apparent that there 
were limited clinicopathological differences at baseline between those receiving 
neoadjuvant CRT and those who did not receive neoadjuvant CRT. Firstly, there were a 
higher proportion of male patients in the neoadjuvant CRT group in comparison to the 
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group not receiving neoadjuvant CRT (85% vs. 64%; p = 0.014), which can be attributed 
to a non-randomized sample. In addition, there were a significantly lower percentage of 
patients with complete excisions in the group who received neoadjuvant CRT (54% vs. 
89%; p > 0.001). This is a counterintuitive result, as the literature suggests that 
neoadjuvant CRT may reduce the size of the primary tumor before surgery, increasing the 
probability of achieving complete surgical margins. Another potential explanation 
includes CRT perhaps being given selectively to patients with clinically larger tumors, 
which had lower probability for complete excision. Lastly, the rate of lymphatic invasion 
was much higher in the group that did not receive neoadjuvant CRT (29% vs. 9%; p = 
0.012). Again, one would hypothesize that neoadjuvant CRT would be preferentially 
offered to patients with lymphatic invasion, but this result may be due to non-randomized 
sampling. 
In terms of overall survival in our study, there was a statistically significant 
improvement for the group that received neoadjuvant CRT (p = 0.049). At the 4-year 
follow up, patients of the neoadjuvant CRT group had a survival of 88.9% compared with 
the adjuvant CRT group having 49.7% of patients remain. With that said, our study was 
retrolective in nature, including many different types of chemotherapy agents and 
radiation regimes without knowing the specific type of chemotherapeutic agent or 
radiation course. This may somewhat account for the differences in our overall survival 
estimates, which tend to be higher in the treatment arm and lower in the control arm when 
compared to other previous positive findings.  
Most of the published randomized trials deny any association between 
neoadjuvant CRT and overall survival for locally advanced rectal cancers. For example, 
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the German Rectal Cancer Study Group found a 5-year overall survival of 76% in their 
group receiving neoadjuvant CRT vs. an overall survival rate of 74% in those without 
neoadjuvant CRT (p=0.8). The study enrolled 823 patients with either stage II or stage III 
disease and subsequently randomized those individuals to receive 5,040 cGy per week 
and concurrent 5-fluorouracil. Patients in the neoadjuvant CRT group then received 
radical surgery with TME six weeks following their CRT. The post-operative group 
received a similar treatment with the exception of a small boost of radiotherapy. The 
study was designed to have 80% power in order to detect a 10% difference in the primary 
end-point, 5-year overall survival. The results of the study prompted a change in clinical 
management due to local control rather than overall survival, which was statistically 
similar between groups. However, the authors note that the benefit in recurrence 
outcomes may have been due to improved compliance, as neoadjuvant radiotherapy was 
more tolerable to patients than the postoperative regime (92% vs. 54%; p < 0.001). A 
similar effect was observed for chemotherapy (89% vs. 50%; p < 0.001).   
With that said, a 2009 randomized controlled trial by Roh et al. did show a non-
significant trend towards improved overall survival for patients receiving neoadjuvant 
CRT when compared with postoperative CRT. The investigators demonstrated a 5-year 
overall survival rate of 74.5% vs. 65.6% in favor of patients receiving neoadjuvant CRT 
(p = 0.065). The Investigators randomized 254 patients with T3 or T4 and/or node 
positive rectal cancers to receive either neoadjuvant CRT consisting of flurouracil and 
leucovorin with 45 Gy in 25 fractions with a 5.40 boost in the original margins or the 
same regime postoperatively no later than four weeks. The neoadjuvant therapy group 
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received surgery after eight weeks post completion of CRT. The primary end points were 
disease-free survival and overall survival.  
A 2013 retrospective study by Tural et al. compared neoadjuvant CRT with 
postoperative CRT in patients with stage II and III rectal cancer. Tural et al. found no 
significant difference between each arm of the intervention, reporting a median overall 
survival of 43.3 months and 47.6 months for both neoadjuvant and postoperative CRT, 
respectively. The 5-year overall survival for this study approximated the estimate 
published in the German Rectal Cancer Study Group paper (71.4% vs. 64.4%; p = 0.9). 
Similar to our study, the data collection was retrospective in design, allowing for error in 
recording and labeling data. Unlike our recruitment strategy, patients were excluded from 
the analysis if positive margins occurred during surgery. Furthermore, no attempt was 
made to control for confounding variables, though the study design was retrospective in 
nature (Tural, 2013). 
A 2014 retrospective cohort study by Wiegering et al., with methodology similar 
to our experiment, analyzed two time periods comparing overall survival between 1993-
2001 and 2002-2010 for patients with locally advanced rectal cancer. The authors 
reported an improved overall survival rate of 79.8% vs. 50.5% (p < 0.0001). This result 
was attributed to neoadjuvant therapy, but also new chemotherapeutic agents and changes 
in surgical method between the two time periods. Another retrospective study published 
in 2016 by Law et al. comparing overall survival over two time periods, 1993-2001 and 
2002 -2011. The study reported an improved overall survival rate of 68.1% in the latter 
period vs. an overall survival rate of 60.2% between 1993-2001 (p = 0.003).  
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 In terms of constructing a multivariate model for overall survival in the present 
study, neoadjuvant CRT was removed from the model for patients with stage II and III 
rectal cancer diagnosed after 2003, as it did not provide a survival benefit with all other 
factors controlled. From the Kaplan Meier plot, the magnitude of the relative risk for 
neoadjuvant CRT suggests benefit (58.2% reduction in mortality), but it failed to achieve 
statistical significance because of inadequate power due to the small sample size of the 
study. To elaborate, the landmark randomized controlled trial by Sauer et al. estimated 
that 680 patients would be required in order to achieve a power of 0.80 and detect a 10% 
difference in overall survival between groups. Our research included 757 patients and it is 
known that observational studies require much larger samples than randomized trials. 
More objectively, the hazard estimates from our results show very wide confidence 
intervals, reflecting that our study is underpowered. Given that an effect size of 58.2% 
reduction in mortality was observed for the group receiving neoadjuvant CRT, one may 
hypothesize that this result could become statistically significant with a much larger 
sample size.  
 With respects to the aforementioned retrospective studies, the 2013 Tural paper did 
not perform a multivariate analysis, limiting the quality of the group’s results. The 2014 
Wiegering paper reported improved overall survival in the latter decade of rectal cancer 
management, but the multivariate model did not include neoadjuvant therapy as a 
significant predictor. Interestingly, the 2016 study by Law et al. found that neoadjuvant 
radiation therapy significantly improved overall survival independent of the time period 
2002- 2011(HR = 0.688; p = 0.011) when included in their multivariate analysis.  
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In terms of the local recurrence-free time to event in our study, there was no 
statistical improvement for individuals receiving neadjuvant CRT, which does not match 
the results observed in the current literature. At 4 years of follow-up, 83.2% of patients 
treated with neoadjuvant CRT were without local recurrence. In comparison, the 4-year 
local recurrence-free time to event for patients not receiving neoadjuvant CRT was 86.9% 
(Log rank (Mantel-Cox) = 0.508; df = 1; p = 0.476). This differs from the findings 
reported in the literature, as the 2004 Sauer et al paper found neoadjuvant CRT to 
improve the rate of local recurrence. The authors reported a 5-year cumulative incidence 
of local recurrence of 13% in the neoadjuvant CRT group vs. 6% in the post-operative 
group (p=0.006). Similar to the German Rectal Cancer group, the 2013 study by Tural et 
al. found a significant improvement in local recurrence rates for patient receiving 
neoadjuvant CRT. The authors found a 5-year local recurrence-free time to event rate of 
89.2% compared to 74.8% in the post-operative CRT group (p = 0.04). As mentioned, 
this study removed patients with positive margins from it’s analysis and despite being 
retrospective in design, the authors made no effort to control for third variables.  
With respects to retrospective studies, the 2009 Roh et al. paper reported a 
cumulative incidence of local recurrence of 10.7% for both neoadjuvant and postoperative 
CRT groups (p = 0.693. In 2014, Wiegering et al. analyzed two time periods, finding a 
lower local recurrence-free time to event rate of 5.3% during 2002 - 2010 compared to 
14.3% during 1993-2001 (p = 0.029). Lastly, Law et al. reported a significantly lower rate 
of local recurrence-free time to event for the period of 2002 – 2011 in comparison to 1993 
– 2001 (5.9% vs. 11.9%; p = 0.002). Neither of the aforementioned retrospective studies 
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performed a multivariate model to rule out third variables to local recurrence free time to 
event. 
With respects to disease-free time to event, our study found no significant benefit 
for neoadjuvant CRT for patients with locally advanced disease diagnosed after 2003 
(Log-rank (Mantel-Cox) = 0.143; df = 1; p = 0.705). At 4 years of follow up, the 
neoadjuvant CRT group had a disease-free time to event rate of 71% whereas the post-
operative group had a disease-free time to event rate of 71.8%. This finding is similar to 
the results of the 2004 Sauer et al. paper resulting in a disease-free time to event rates of 
68% for patients randomized to receive neoadjuvant CRT and 65% for patients given 
post-operative CRT (p = 0.32). Similarly, the 2013 paper by Tural et al. reports no 
statistical benefit for disease-free time event, with rates of 81.7% in the neoadjuvant CRT 
group in comparison to 68.5% in the post-operative CRT group (p = 0.1). In contrast, the 
study by Roh et al. reported an improved disease-free time to event rate of 64.7% for 
patients receiving neoadjuvant CRT verses 53.4% for post-operative CRT patients (P = 
0.011). The 2014 Wiegering study reported an improved disease-free time to event rate of 
19% during 1993 – 2001 in comparison to 32% during 2002 – 2010 (p = 0.0035). The 
2016 study by Law et al. did not perform a disease-free time to event analysis. As 
mentioned, these latter two studies did not perform multivariate models for disease-free 
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5.5 Conclusions of study and future directions 
With respects to our study, a portion of the data were collected from retrospective 
chart audits.  A criticism of this research would be that retrospective methods are prone to 
error when recording information from patient files. Specifically, there is potential for 
human error whenever patient information is being read from a chart that may be illegible 
or documented incorrectly by hospital staff. In addition, this experiment involved three 
different patient samples with multiple individuals involved in data entry, which can lead 
to discrepancy in the recording and accuracy of said information. Similarly, any data 
collector could potentially input an incorrect value when transferring this information 
collected from the chart into our dataset. Although the same chart abstraction form was 
incorporated at all sites, incongruent labeling of variables in datasets could lead to error 
when combining data. A further limitation of the study is the fact that only 1 of 3 data 
sources includes patients treated during the entire timespan of interest when the research 
question is to evaluate the changes in treatment over time.  
Another notable limitation is that the OFCCR cohort did not incorporate proxy 
consent when recruiting patients to the study. As a result, post-mortem file abstraction 
could not be performed. The patient sample that was accrued had a higher proportion of 
stage I disease in comparison to other cohorts with low rates of lymphovascular and 
perineural invasion. In addition, the observational study design does not account for 
general improvements in medical care over time, including surgical advancements related 
to locally advanced rectal cancer. Ultimately, this makes it difficult to examine 
differences in survival due to neoadjuvant CRT without the use of a control group. 
Although our analysis provided regression accounting for stage and invasion status, 
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patients of the OFCCR cohort may have favorable prognostic factors that were not 
accounted for in the survival and time to event analyses leading to bias among our results. 
Ultimately, this bias would not affect those patients diagnosed with locally advanced 
staged disease, which is the main group of interest.  
A major weakness of this study would be the lack of information collected with 
respects to CRT regime and timing of surgery post therapy in our cohorts. Many other 
studies ensure that a standardized regime is followed, though these studies are also 
prospective design. With our analysis, it is difficult to identify how many patients 
received a certain chemotherapeutic agent and the duration that drug during treatment. In 
addition, the results suggest that patients who received neoadjuvant CRT were less likely 
to have complete excisions. As mentioned previously, this result could be due to the 
possibility of selective use of neoadjuvant CRT in stage II and III patients with worse 
prognosis and this could have made it more difficult to demonstrate a survival benefit for 
neoadjuvant CRT. In addition, measures of overall survival incorporate all cause 
mortality with no adjustment for cancer-specific death. Although overall survival 
provides an estimation of cancer-specific death for this patient population, the rate of 
rectal cancer, comorbid disease, and incidental death will underestimate the rate of 
cancer-specific survival. With that said, overall survival is the outcome used in many 
studies to address this research question, but some papers do also analyze cancer-specific 
mortality, somewhat limiting the generalizability of our findings. Furthermore, the results 
suggest that there is a significant difference between the single practice cohort and the 
cancer registry cohorts with respects to the both the rate of anterior resection surgeries 
and complete resections. This may further limit the generalizability of our results to other 
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studies in the available literature. This patient sample comes from a single person’s 
practice and differences in survival may be due to surgeon-specific variables not 
accounted for in our analysis. Another issue is related to the data of the surgeon’s 
practice, which would suggest that prior to December 2003, a significant proportion of 
the patients in the single practice were already receiving neoadjuvant CRT (29% vs. 39%; 
prior to December 2003 vs. after December 2003). This would certainly make it more 
difficult to demonstrate significant changes in the rate of neoadjuvant CRT over time. 
Many other variables exist that were not incorporated in our analysis, such as the rate of 
surgical complications and adherence to CRT regime, which could act as confounding 
variables. Lastly, multiple tests were included in this study, which increases the 
probability of finding a significant result in at least one of the many analyses performed; 
the probability of type 1 error increases with the number of tests included in the analysis. 
This is particularly important as the survival curve showing potential benefit for neo-
adjuvant CRT in stage II/III disease just reaches statistical significance at p=0.049. The 
higher p-value in the setting of multiple tests could potentially result from an increased 
probability of type I error and this is a limitation of the findings of this research. 
Our research suggests a trend in improved survival for patients with stage II and 
III rectal cancer who received neoadjuvant CRT. However, this study was not able to 
achieve a statistically significant result due to a small sample size lacking the appropriate 
power to make such a conclusion. Studies exist that evaluate CRT directly (neoadjuvant 
CRT vs. postoperative CRT) in randomized controlled trials and by comparing the 
decades before and after the implementation of neoadjuvant regimes in cohort designs. 
While most direct comparisons of CRT suggest that neoadjuvant therapy offers no 
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survival benefit for stage II and III patients with rectal cancer, there are mixed findings 
when comparing survival between the decades before and after implementation of 
neoadjuvant regimes. With that said, there is still a need for further evaluation of clinical 
practice before and after the implementation of neoadjuvant therapy, especially when 
considering that our study was able to show a survival result trending towards 
significance. Future studies should include cohort designs with adequate sample size to 
detect significant mortality benefit or meta-analyses of existing findings. An attempt 
should be made to standardize proxy consent status between participating samples and 
documenting the specific type of chemotherapeutic agents used. The strengths of our 
study includes a representative sample of patients with rectal cancer enrolled from 
multiple population-based registries, the standardization and quality assurance involved in 
our data collection, and the level of comparison involved in describing results across 
multiple cohorts and time periods. Again, neoadjuvant CRT had no statistically 
significant effect on mortality related to stage II and III rectal cancer. However, the 
relative risk of death was 57% lower for patients with locally advanced disease receiving 
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Ontario Familial Colon Cancer Registry Treatment and Outcome Study 
CLINICAL DIAGNOSIS AND TREATMENT FORM 
 








 LAST      FIRST 
 














1. Place of Diagnosis: 
 Name City or Town MOH Code 







2. Site of Cancer(s): 
 




Site Name 4-Digit ICD-9 
Code 
1.   
2.   
3.   
4.   
5.   
 
3. Date of initial diagnosis of colorectal cancer (please use histological date i.e. Date of pathology 
report): 







   
4. Preoperative symptoms (please check all that apply): 





  Weight Loss 
















5. Method of colorectal cancer diagnosis: 
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  Colonoscopy 
  Rigid sigmoidoscopy 
  Flexible sigmoidoscopy 
  Sigmoidoscopy NOS 
  Barium enema 
  Chest x-ray 
  Chest CT scan 
  Abdominal/Pelvic CT scan 
  Ultrasound 




6. Type of definitive surgery for colorectal cancer (SEER coding used) (please attach all pathology and 
operative reports for this colorectal cancer): 
  None  
  Local tumour destruction, i.e. laser, electrocautery 
  Local surgical excision with specimen i.e. polypectomy, snare 
  Segmental resection, not hemi-colectomy i.e. cecectomy, appendectomy, 
sigmoidectomy, partial resection of transverse colon and flexures, 
iliocolectomy, enterocolectomy, partial colectomy, NOS 
  Low Anterior 
  Hemi-colectomy, but not total. Right or left, must include a portion of 
transverse colon 
  Abdominoperineal resection 
  Total or subtotal colectomy, not rectum 
  Colectomy NOS 
  Segmental colectomy + other organs (*Please specify below) 
  Hemi-colectomy + other organs (*Please specify below) 
  Total or subtotal colectomy or + other organs (*Please specify below) 
  Abdominoperineal resection + other organs (*Please specify below) 









*If Other Organs were removed: 
 




  Appendix (not a part of colon resection) 
  Stomach 
  Pancreas 
  Small intestine 
  Liver 















7. If no surgery was performed, reason:  
  Patient Refusal 
  Antecedent Death 
  Medical Contraindication 













9. If pN1 or greater (if pN0 pls. go to #14):  
 
   
139 
Number of Nodes Reported  
Number of Nodes Positive  
 







11. Stage of disease at initial diagnosis (from all information available) 
  Stage 0 
  Stage 1 
  Stage 2 
  Stage 3 
  Stage 4 
  Unknown 
 
12. Other Pathology Identified:   
Yes Type: No Unknown 
    Crohn’s Disease 
  Ulcerative colitis 
  Diverticulosis/it is 
  Perforation 




13. Preoperative CEA (carcinoembryonic antigen):  











14. Date of Blood Test for Preoperative CEA: 
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15. Date of surgery: 








16. Primary surgery hospital:  
Name City or Town MOH Code 
   
 
17. Operating Surgeon: 
 
 
18. Operative findings, local (residual tumour) (please obtain information from the operative 
report and/or the discharge summary) 
  Tumour not entirely resected 

















19. Operative findings, Distant (pls. obtain info. from the operative report &/or the discharge 
summary): 
 








Type of Metastatic Disease Found: Unknown 
      Ascites 
  Mesenteric nodes, other than in 
mesentery of planned resection 
  Liver  
  Lung 
  Omentum 













    Proximal 
  Distal 
  Radial 
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(CONCURRENT) PRIMARY DIAGNOSIS #_________ Please see Ques.#2 
to identify Site #. 
(Please complete a separate form for each primary diagnosis).  
 












          
 




  Signet ring cell 




23. Vascular Invasion: 




24. Lymphatic Invasion: 




25. Perineural Invasion: 
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26. Patient Enrolled in a clinical trial: 










28. Chemotherapy given (If yes, pls. complete Treatment table below & attach  
all flow sheets):  
Ye
s 




















CHEMOTHERAPY TREATMENT (For cyclic chemo., pls. report each cycle 
separately e.g. 1, 2, 3, 4) 
FOR BASELINE DIAGNOSIS 
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32. Radiation given (please attach all flow sheets, where available): 








CLINICAL FOLLOW-UP SINCE BASELINE DIAGNOSIS 
 
33. New cancer event in the four years following the initial diagnosis: 
Yes Check off as many that apply and complete the 
corresponding section. 
None Unknown 
    Locoregional Recurrence  
  Distant Recurrence 
  Other Non-Colorectal Primary  




34. Patient Enrolled in a clinical trial since baseline: 
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FIRST LOCOREGIONAL RECURRENCE 
 
  None (go to #43) 
 
If applicable, please attach copies of documentation (i.e. radiology reports, clinic notes, pathology 
reports, operative reports, etc.) with the date of first detection of site(s) of first locoregional 
recurrence(s). 
 
35. Sites of involvement at time of first locoregional recurrence (please check off 
all that apply): 











  Anastomosis    
  Mesentery    
  Abdominal Wall (not incisional)    
  Incisional    
  Pelvis      




   
  Unknown    
 
36. Surgery for locoregional recurrence: 
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39. Chemotherapy given (If yes, pls. complete Treatment table below & attach  
all flow sheets):  
Ye
s 




















CHEMOTHERAPY TREATMENT (For cyclic chemo., pls. report each cycle 
separately e.g. 1, 2, 3, 4) 
FOR FIRST LOCOREGIONAL RECURRENCE 




























































































































































































































































































































































































40. Radiation given (please attach all flow sheets, where available): 
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41. Other treatment given (please attach all documents): 





42. Other Locoregional recurrence sites after the first site was identified (please 
check off all that apply): 








  Anastomosis    
  Mesentery    
  Abdominal Wall (not incisional)    
  Incisional    
  Pelvis      




   
  Unknown    
 
FIRST DISTANT RECURRENCE 
 
  None (go to #51) 
 
If applicable, please attach copies of documentation (i.e. radiology reports, clinic 
notes, pathology reports, operative reports, etc.) with the date of first detection 
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43. Sites of involvement at time of first distant recurrence (please check off all 
that apply): 











  Liver    
  Lung    
  Bone    
  Ascites    
  Non-mesenteric lymph nodes 




   
  Supraclavicular nodes    
  Brain    
  Skin, except incision 
Please specify: 
_____________________ 
   




   
 
44. Surgery for distant recurrence: 
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47. Chemotherapy given (If yes, pls. complete Treatment table below & attach  
all flow sheets):  
Ye
s 




















CHEMOTHERAPY TREATMENT (For cyclic chemo., pls. report each cycle 
separately e.g. 1, 2, 3, 4) 
FOR FIRST DISTANT RECURRENCE 












































































































































































































































































































































































48. Radiation given (please attach all flow sheets, where available): 








49. Other treatment given (please attach all documents): 
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50. Other Distant recurrence sites after the first site was identified (please check 
off all that apply): 








  Liver    
  Lung    
  Bone    
  Ascites    
  Non-mesenteric lymph nodes 




   
  Supraclavicular nodes    
  Brain    
  Skin, except incision 
Please specify: 
_____________________ 
   




   
 
OTHER NON-COLORECTAL PRIMARY(S) 
 
  None (go to #55) 
 
51. Hospital of Diagnosis: 
 Name City or Town MOH Code 
   
 
52. Sites of new Non-Colorectal Primary Cancer(s) since the initial diagnosis of 
Colorectal cancer: 
Cancer Site 4-Digit ICD-9 
Code 
1.   
2.   
3.   
4.   
5.   
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53. Date(s) of diagnosis of new Non-Colorectal Primary Cancer(s) (please use histological date): 
Cance
r 
Day Month Year 
1.    
2.    
3.    
4.    
5.    
 





Stage 1 Stage 2  Stage 3 Stage 4 Unknown 
1.             
2.             
3.             
4.             
5.             
 
NEW COLORECTAL PRIMARY(S) 
 
  None (go to #80) 
 
 
55. Site of Cancer(s): 
Cancer Site 
Name 







1.        
2.        
3.        
4.        
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56. Preoperative symptoms (please check all that apply): 





  Weight Loss 




57. Method of colorectal cancer diagnosis (check all that apply): 
  Colonoscopy 
  Rigid sigmoidoscopy 
  Flexible sigmoidoscopy 
  Sigmoidoscopy NOS 
  Barium enema 
  Chest x-ray 
  Chest CT scan 
  Abdominal CT scan 
  Ultrasound 




58. Type of definitive surgery for colorectal cancer (SEER coding used) (please attach all 
pathology and operative reports for this colorectal cancer): 
  None (please go to #18) 
  Local tumour destruction, i.e. laser, electrocautery 
  Local surgical excision with specimen i.e. polypectomy, snare 
  Segmental resection, not hemi-colectomy i.e. cecectomy, appendectomy, 
sigmoidectomy, partial resection of transverse colon and flexures, 
iliocolectomy, enterocolectomy, partial colectomy, NOS 
  Low Anterior 
  Hemi-colectomy, but not total. Right or left, must include a portion of 
transverse colon 
  Abdominoperineal resection 
  Total or subtotal colectomy, not rectum 
  Colectomy NOS 
  Segmental colectomy + other organs (*Please specify below) 
  Hemi-colectomy + other organs (*Please specify below) 
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  Total or subtotal colectomy or + other organs (*Please specify below) 
  Abdominoperineal resection + other organs (*Please specify below) 





*If Other Organs were removed: 
  Spleen 
  Gallbladder 
  Appendix (not a part of colon resection) 
  Stomach 
  Pancreas 
  Small intestine 
  Liver 














59. If no surgery was performed, reason:  
  Patient Refusal 
  Antecedent Death 
  Medical Contraindication 














61. If pN1 or greater (if pN0 pls. go to #D8):  
Number of Nodes Reported  
Number of Nodes Positive  
 







63. Stage of disease at initial diagnosis (from all information available) 
  Stage 0 
  Stage 1 
  Stage 2 
  Stage 3 
  Stage 4 
  Unknown 
 
64. Other Pathology Identified:   
Yes Type: No Unkno
wn 
    Crohn’s Disease 
  Ulcerative colitis 
  Diverticulosis/it is 
  Perforation 




65. Preoperative CEA (carcinoembryonic antigen):  
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66. Date of Blood Test for Preoperative CEA: 








67. Date of surgery: 








68. Primary surgery hospital:  
Name City or Town MOH Code 
   
 
69. Operating Surgeon: 
 
 
70. Operative findings, local (residual tumour) (please obtain information from the operative 
report and/or the discharge summary) 
  Tumour not entirely resected 
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Type of Metastatic Disease Found: Unknown 
      Ascites 
  Mesenteric nodes, other than in 
mesentery of planned resection 
  Liver  
  Lung 
  Omentum 













    Proximal 
  Distal 
  Radial 
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(CONCURRENT) PRIMARY DIAGNOSIS #_________ Please see Ques.#5 
to identify Site #. 
(Please complete a separate form for each primary diagnosis).  
 












          
 




  Signet ring cell 




75. Vascular Invasion: 




76. Lymphatic Invasion: 




77. Perineural Invasion: 
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79. Chemotherapy given (If yes, pls. complete Treatment table below & attach  
all flow sheets):  
Ye
s 




















CHEMOTHERAPY TREATMENT (For cyclic chemo., pls. report each cycle 
separately e.g. 1, 2, 3, 4) 
FOR NEW CRC PRIMARY 
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79. Radiation given (please attach all flow sheets, where available): 




















81. Cause of Death (please attach copy of death certificate if available): 
  Colorectal cancer 
  Other, No colorectal present    Please specify: 
________________________________________ 









83. Location of Death: 
  Hospital      Please specify: 
________________________________________________________ 
  Home          
  Hospice      Please specify: 
________________________________________________________ 





DATE OF FINAL CHART NOTE:         
 
PATIENT HAS BEEN REFERRED TO THE CARE OF: DR.     
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         Date form Completed:   _____ ______ ______ (dd/mmm/yyyy) 
 
         Abstractor’s Initials: _____ ______ 
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